# NASSAU HEALTH CARE CORPORATION a/k/a the NuHealth System

# Request for Proposals for

### REFERENCE LAB SERVICES

### RFP 2018-009

### **Contact and Submission:**

Rachel Robbins, M.D.
Nassau Health Care Corporation
2201 Hempstead Turnpike
East Meadow, NY 11554
(516) 572-3205
rrobbins@numc.edu

\*ALL WRITTEN COMMUNICATIONS IN CONNECTION WITH THIS RFP, INCLUDING EMAILS, MUST CONTAIN THE TITLE OF THE RFP AND CORRESPONDING NUMBER SET FORTH ABOVE, IN THE SUBJECT LINE OF SUCH COMMUNICATIONS

# **Anticipated Schedule:**

• Issue RFP July 26, 2018.

• Deadline for Questions August 8, 2018.

• Proposals Due August 22, 2018

• Interviews, if required To be determined

Dates indicated above are subject to change at the sole discretion of Nassau Health Care Corporation.

### **SCHEDULE A**

### **DESCRIPTION OF SERVICES SOUGHT**

Please read the full text of the Request for Proposals to which this Schedule is attached for important information concerning the terms of this Request for Proposals and additional required information.

### 1. Introduction/Background

Nassau Health Care Corporation ("NHCC"), also known as the NuHealth System, is a New York State public benefit corporation created by the New York State Public Authorities Law. NHCC operates Nassau University Medical Center, a 530-bed tertiary care teaching hospital ("NUMC") and the A. Holly Patterson Extended Care Facility ("AHP"), a 589-bed skilled nursing facility. Additionally, NHCC co-operates various Community Health Practices in partnership with Long Island FQHC, Inc., a non-profit, consumer-driven organization created to help address the health needs of the region's most vulnerable populations. NHCC is affiliated with Northwell Health (formerly known as the North Shore-Long Island Jewish Health System) and the Health Sciences Center of the State University of New York at Stony Brook and maintains a strong commitment to the education of healthcare providers.

NUMC has been the primary source of medical care for millions of Nassau County residents since 1935. With its 19-story main tower, NUMC is Nassau County's tallest building and a familiar Long Island landmark. As the region's premier Level I trauma center, NUMC treats many of the County's most critically injured patients, and has long carried the responsibility of being the region's "safety net" hospital. Additionally, NUMC maintains a strong commitment to medical education. NHCC is academically affiliated with the Northwell Health, the Health Sciences Center of the State University of New York at Stony Brook, the New York Institute of Technology College of Osteopathic Medicine, the New York College of Podiatric Medicine, and the American University of the Caribbean School of Medicine.

AHP is recognized nationally as a model for skilled nursing facilities. AHP offers innovative care in an environment that treats the 'whole' person. The skilled and caring medical staff responds to the physical, social and emotional needs of each resident.

NHCC's Community Health Practices are bringing a new kind of care to the communities that need it most. It is the goal of NHCC to see that every Long Islander has a "medical home" - a place where people you know provide the kind of primary and preventative care that safeguards the health of you and your family.

### 2. Scope of Services

The Scope of Services ("Scope") outlined below has been established for the purpose of achieving and implementing program goals and objectives described in this document. Although the Scope is intended to serve as a reference in the preparation of the proposal, forthcoming proposals may offer additional services which support the goals of this RFP.

### **SERVICES**

- 1. Laboratory tests to be performed upon request.
- 2. The selected vendor shall provide qualified and trained personnel and certified/licensed facilities for medical laboratory diagnostic testing and services. In addition the selected vendor will identify a dedicated account representative.
- 3. The required tests are listed in the attached schedules: 1. Laboratory; 2. Pathology; 3. NIDA; 4. Stat TAT 2 hour (as needed); 5. Other tests (as needed). Proposals must include completed schedules, including turn-around time ("TAT"), pricing and the performing lab. The schedules are not intended to limit the tests that may be required, and proposals should address the addition of other tests.
- 4. Proposals must provide for courier pick-up of specimens, on a coordinated basis, from NUMC and clinics. Proposals should include a defined turnaround time. Specimen pickup shall be at the discretion of NUMC, to address operational and patient needs; there should be no additional charge for stat pickup requests.
- 5. Proposals should presume that the majority of test orders and results will be communicated via a CPU interface, but there must be provision for manual test orders reported to a dedicated printer and to a web based portal product.
- 6. The proposals shall include a list of all reference laboratories and their respective licenses (in addition to their identification in the schedules of tests); the selected vendor will update this list through the duration of the contract.
- 7. The selected vendor will timely notify NUMC regarding test changes, including but not limited to changes in the performing location, equipment, test requirement, and test code.
- 8. Proposals should address the communication of critical and/or alert values.
- 9. Proposals should include a listing of other value added aspects of service including, but not limited to, decision making tools concerning indications for use, result

- interpretation, and downstream decision making. The proposal shall describe how the vendor will support and facilitate NUMC's ability to monitor and drive our appropriate utilization and drive physician behavior.
- 10. Proposer must be approved and permitted by New York State Department of Health ("NYS DOH") for all testing required in this RFP. If any testing is not approved, it will be sent to a laboratory that is approved by NYS DOH.
- 11. The successful proposer will provide laboratory testing, with rapid turnaround, for stat and urgent testing needs in situations in which NUMC equipment cannot be used.

### EQUIPMENT

- 12. The selected vendor shall provide peripheral supplies such as vacutainers, needles, urine containers, as permitted by law, at no additional charge.
- 13. The selected vendor will provide to NUMC, at no cost, remote teleprinter and access to a web based solution for: orders/results/viewing/information access/ reporting options. The selected vendor shall provide the equipment necessary to report results to include connectivity (electronic order and result reporting via interface with NUMC systems) and supplies, at no charge to NUMC. Proposals shall include description of information technology infrastructure: data-systems capabilities (current LIS interfaces) desktop workstations, web-based inquiries, and physician-user connectivity solutions. The selected vendor will supply all laboratory data access consumables related to vendor –owned equipment, at no cost to NUMC for the contract period.
- 14. The selected vendor will be responsible for the costs of maintenance, repair and service of vendor-owned equipment.
- 15. The selected vendor shall provide bidirectional CPU interface with NUMC's current lab information system, and must match the total quantity of reference tests currently built on the existing interface.

### REPORTS/PRICING

- 16. The selected contractor will be responsible for billing third party payors (i.e. Medicaid) where mandated by applicable law. In no event, shall the selected contractor be permitted to invoice or charge NHCC for such testing.
- 17. Proposals should address the possibility of NHCC requesting a test be referred to a specific outside laboratory.
- 18. Monthly utilization reports will be required from the selected vendor. The selected vendor shall provide quality management reports to be determined as per accrediting agencies. Billing shall include both tests ordered for each patient and by test code, separately.
- 19. The selected vendor will be required to provide turnaround time report (TAT report) and test not performed report (TNP report) monthly; summary of proficiency tests, corrected report summary, call center telephone response times will be provided quarterly.
- 20. The selected vendor will provide NUMC with unique user id so the laboratory can have access to a referral EHR database to allow access to patient results, status of tests online, test directory of available tests performed and specimen requirements for these tests.
- 21. The proposal should be for a term of at least 3 years but no more than 5 years.

# NASSAU HEALTH CARE CORPORATION REQUEST FOR PROPOSALS

## I. Proposal/Process To Be Followed

NHCC is requesting proposals for the services described in this Request for Proposals ("RFP"). Proposals shall be prepared and submitted as outlined below; proposals that do not conform to these requirements may be disqualified.

This RFP is available to interested parties through the NHCC office designated in above. It may also be downloaded by clicking on the "Doing Business with NuHealth" link found on the NHCC website at <a href="www.numc.edu">www.numc.edu</a>. All requests for information concerning this RFP should be directed to the contact office designated above in writing by the due date for information requests specified above, or if no date is specified, Seven (7) days prior to the due date for proposals.

### **PROPOSERS MUST SUBMIT:**

- ONE (1) ORIGINAL AND FOUR (4) COPIES, AND ONE (1) COPY ON CD OR FLASH DRIVE [clearly labeled on the outside of the drive] OF THE PROPOSAL TO THE NHCC CONTACT PERSON BY 3:00 P.M. ON THE DUE DATE SPECIFIED AND
- ONE (1) ADDITIONAL COPY OF THE PROPOSAL ON CD OR FLASH DRIVE MUST BE SUBMITTED TO:

NASSAU HEALTH CARE CORPORATION DEPARTMENT OF LEGAL AFFAIRS – 19<sup>TH</sup> floor 2201 HEMPSTEAD TURNPIKE EAST MEADOW, NY 11554

ELECTRONIC OR FACSIMILE PROPOSALS WILL NOT BE ACCEPTED. FAILURE TO SUBMIT ALL DOCUMENTS AND ELECTRONIC MEDIA AS REQUIRED MAY RESULT IN REJECTION OF YOUR PROPOSAL.

Each written proposal must include all the information outlined in this RFP, including completion and submission of the forms attached in Appendix I to this RFP. The selected Proposer will enter into negotiations with NHCC regarding the specific terms of an appropriate agreement. If agreement cannot be reached with a selected Proposer within a reasonable time, NHCC may reject that Proposer and commence negotiations with one or more other Proposers.

Proposals are to be prepared in such a way as to provide a straightforward, concise description of capabilities to satisfy the requirements of this RFP. Expensive bindings, colored displays, promotional materials, etc., are neither necessary nor desired. Emphasis should be concentrated on conformance to the RFP instructions, responsiveness to the RFP requirements, and on completeness and clarity of content.

### II. Contents of Proposals

- A. Name of the Proposer.
- B. Contact person for the Proposer, including name, address, phone and fax numbers, e-mail address and other contact information.
- C. Background information regarding the Proposer, including:
  - 1. Brief history of the Proposer's firm and a description of all services it provides.
  - 2. A summary description of its organizational structure (e.g., corporation, partnership, LLC, etc.), its history (including information on the date of its formation and the State of its formation), its management and ownership structure (including the name and address

- of its officers, and of each person, directly or indirectly holding a five (5%) percent or greater ownership interest in the Proposer.
- 3. Proposer shall provide documentation satisfactory to NHCC demonstrating that Proposer is licensed and authorized to do business in the State of New York and, if applicable, Nassau County.
- 4. A description of the Proposer's existing business operations, including number of employees by discipline.
- 5. Proposals must demonstrate the qualifications and experience of the Proposer specifically related to the services contemplated by this RFP.
- 6. Each proposal must include Proposer's financial information. This information is needed to ensure that each Proposer will be capable of performing its obligations under any agreement entered into between the Proposer and NHCC. Demonstration of the applicant's financial soundness shall be established by submitting the following information:
  - a. A copy of the Proposer's most recent annual audited financial statement and annual audited financial statements for the previous two years.
  - b. Copies of the Proposer's subsequent quarterly financial reports.
  - c. Detailed information of any changes in the mode of conducting the Proposer's business, including bankruptcy proceedings or filings, and merges or acquisitions within the past three (3) years.
  - d. List of any bankruptcy proceedings in the past ten (10) years initiated by or against the Proposer or any affiliate or related company.
- 7. At least three business references (including names of individuals, their titles, organizations, mailing addresses, telephone and fax numbers, and e-mail addresses).
- 8. A Proposer that is a licensed health care provider or other licensed entity must include information concerning any material negative findings, sanctions imposed or pending regulatory or legal proceedings.
- 9. Proposals must include the following:

- a. List of any and all criminal convictions within the last (10) ten years rendered against the Proposer, any officer or director thereof, or any affiliate or related company.
- b. List of any and all civil penalties, judgments, consent decrees, violations, Statements of Deficiency or other sanctions within the last ten (10) years rendered against the applicant, any officer or director thereof, or any affiliate or related company.
- c. List of any and all current investigations, indictments or pending litigation by any Federal, State or local jurisdiction initiated against the applicant, any officer or director thereof, or any affiliate or related company.
- d. List of any and all actions occurring with the last ten (10) years which have resulted in revocation or suspension of any permit or authority to do business in any Federal, State, or local jurisdiction, by the applicant, any officer or director thereof, or any affiliate or related company.
- e. List of any and all actions occurring in the past ten (10) years that have resulted in the barring from public proposal submission of the applicant, any officer or director thereof, or any affiliate or related company.
- D. Qualifications of Proposer to carry out this project or to provide these services, including a list of comparable projects and identification of individuals (including their names, titles, organizations, mailing addresses, telephone, fax numbers, and e-mail addresses) who may be contacted with respect to each comparable project.
  - 1. Provide adequate information demonstrating experience on projects of similar scope and magnitude. Project start/completion dates and owner/client reference must be included.
  - 2. List all projects Proposer has completed (or are in progress) for the past eighteen (18) months. Give a brief description of each project, including owner, size of facility, type of work performed, and size of project and completion date.
  - 3. List the five (5) similar projects Proposer's firm has completed (or are in progress). Give a brief description of each project; include the size of the facility, owner and owner contact to be used for reference purposes. Also include project start and completion (proposed) date.
- E. The qualifications and experience of Proposer's staff and management for the project, including any proposed sub-contractors.

- 1. List the professional and support positions and number or personnel in each position. Provide resumes for all key staff and subcontractors (resumes must be no longer than two pages per individual).
- 2. Provide an organizational chart that includes all personnel who will be committed to this project. Provide specific information as to their experience on projects similar to this one. For the project manager identified as part of the project team, provide the name and contact information of three clients with whom that person has worked on a similar project.
- 3. List any professional sub-consultants that you intend to propose to provide services not available directly from your firm. Provide specific information documenting their work on similar projects.
- F. Scope of proposed services, including work plan and methodology.
- G. Fee and cost proposal that shall clearly identify and specify all elements of cost that would become charges to NHCC, in whatever form. Provide information on your billing practices, including reimbursable cost categories.
- H. List your general liability and professional liability insurance coverage.
- I. Any contingencies or conditions on the proposal.
- J. Information required in Appendix I to this RFP.
- K. Conflict of Interest
  - 1. Please disclose:
- a. Any material financial relationship that any employee of your firm has with any entity that may create a conflict of interest or the appearance of a conflict of interest in acting as contractor on behalf of NHCC.
- b. Any family relationship that any employee of your firm has with any corporation, individual or other entity that may create a conflict of interest or the appearance of a conflict of interest in acting as contractor to NHCC.
- c. Any other matter that your firm believes may create a conflict of interest or the appearance of a conflict of interest in acting as contractor on behalf of NHCC.
- 2. Please describe any procedures your firm either has, or would adopt, to assure NHCC that a conflict of interest would not exist for your firm in the future.

### III. Confidential Information

The New York State "Freedom of Information Law," Public Officers Law Article 6, permits access to government records and may permit public access to proposals submitted in response to this RFP. To protect any portion of responses that constitutes technical, financial or other data whose public disclosure would cause substantial injury to a Proposer's competitive position, or would constitute disclosure of a trade secret, a Proposer must designate any sections of its proposal that meet those criteria. NHCC assumes no responsibility for disclosure of unmarked data for any purpose. NHCC will review such designations in making its determination whether disclosure is required, which determination shall be binding on the Proposer.

### IV. Anti-discrimination and MWBE Participation

It is the policy of NHCC to comply with all federal, state and local laws, policies, orders, rules and regulations which prohibit unlawful discrimination because of race, creed, color, national origin, sex, sexual orientation, age, disability, or marital status, and to take affirmative action in working with contracting parties to ensure that Minority and Women-owned Business Enterprises (MWBEs), Minority Group Members and women share in the economic opportunities generated by NHCC's participation in projects or initiatives, and/or use of NHCC funds. NHCC's anti-discrimination or other policies that promote equal opportunities shall apply to this initiative and MWBEs are encouraged to submit proposals.

Pursuant to New York State Executive Law Article 15-A, NHCC recognizes its obligations under the law to promote opportunities for maximum feasible participation of certified minority-and women-owned business enterprises (M/WBEs) and the employment of minority group members and women in the performance of NHCC contracts.

The selected contractor shall be required to use good faith efforts to achieve the participation of certified MWBE's as specified in this RFP or Bid, and if no participation goal is explicitly specified, participation amounting to 20% of the total value of the fees received by the contractor shall be the goal. As part of their proposal, respondents are required to include a completed MWBE Utilization Plan (the "Plan") using the form attached in Appendix I as part of their proposal. The Plan shall list each MWBE the respondent intends to utilize to perform the contract, a description of the scope of work to be performed by each MWBE, and the estimated or, if known, actual dollar amounts to be paid to each MWBE. Respondents should endeavor to utilize MWBEs as subcontractors, subconsultants, suppliers, and/or enter into joint venture or teaming agreements with M/WBEs in order to comply with the MWBE utilization goals. In the event that a respondent is a certified MWBE the respondent should list itself in the Plan

as performing 100% of the contract work and is not required to subcontract with other MWBE firms.

### V. Procurement Law Requirements

State Finance Law §§ 139-j and 139-k (collectively, the "Procurement Requirements") apply to this RFP. The Procurement Requirements (1) govern permissible communications between potential respondents and NHCC with respect to this RFP during the procurement process; and (2) establish sanctions for knowing and willful violations of the provisions of the Procurement Requirements, including disqualification from eligibility for an award of any contract pursuant to this solicitation.

Compliance with the Procurement Requirements requires that (a) all communications regarding this RFP, from the issuance of this RFP through final award and approval of any resulting contract (the "Restricted Period"), be conducted only with the contact person(s) listed; (b) the completion by respondents of the Disclosure of Prior Non-Responsibility Determinations and the Affirmation of Understanding of and Agreement pursuant to State Finance Law, copies of which are attached to this RFP as attachments to Appendix I, and (c) periodic updating of such forms during the terms of any contract resulting from this RFP. Respondents must submit both of these forms, properly completed, as The Procurement Requirements also require NHCC part of their proposals. employees to obtain and report certain information when contacted by prospective bidders during the Restricted Period, make a determination of the responsibility of bidders and make all such information publicly available in accordance with applicable law. If a prospective bidder is found to have knowingly and willfully violated the State Finance Law provisions, that prospective bidder and its subsidiaries, related or successor entities will be determined to be a nonresponsible bidder and will not be awarded any contract issued pursuant to this RFP.

More information about State Finance Law Sections 139-j and 139-k can be found at <a href="http://www.ogs.ny.gov/aboutOgs/regulations/defaultSFL\_139j-k.asp">http://www.ogs.ny.gov/aboutOgs/regulations/defaultSFL\_139j-k.asp</a>.

All potential Respondents are solely responsible for full compliance with the Procurement Requirements.

### VI. Selection Criteria

Proposals from responsible parties will be reviewed and evaluated from the point of view of cost, qualifications, references and other appropriate factors relevant to: (i) the Proposer's ability to provide the services; (ii) the anticipated quality of the services to be provided; and (iii) financial and other benefits to NHCC.

### VII. Terms and Conditions

- A. This RFP constitutes an invitation to make proposals to NHCC. Accordingly, this RFP does not commit NHCC to award a contract, or to procure, or to contract for services or supplies. Notwithstanding any other provisions of this RFP, NHCC reserves the right to award this contract to the vendor(s) that best meet the requirements of the RFP, and not necessarily to the lowest proposer. NHCC reserves the right to accept or reject any or all proposals received as a result of this request; to negotiate with all qualified sources; or to cancel in part or in its entirety this RFP if it is in the interests of NHCC to so do. NHCC reserves and, in its sole discretion, may exercise any or all of the following rights and options with respect to this RFP, any proposals and any related agreements, without incurring any liability to Proposers:
  - 1. NHCC reserves the right to disqualify any and all proposals that fail to meet the requirements specified in this RFP.
  - 2. NHCC reserves the right to determine whether to interview some or all of the Proposers, and to conduct such interviews privately.
  - 3. NHCC reserves the right to select and enter into a contract with the Proposer whose proposal best satisfies NHCC's overall interests.
  - 4. Because this RFP is not a "competitive bid" process, the Proposer submitting the lowest cost proposal, or the proposal projecting the greatest financial benefit to NHCC, may not necessarily be selected. NHCC instead reserves the right to select the proposal it believes to be most beneficial to NHCC, with financial terms not being the sole determinative factor. NHCC's decision-making and selection process will be discretionary and will be based on a variety of factors. By submission of its proposal, each Proposer expressly understands, acknowledges and accepts that this is not a "competitive bid" process, and that NHCC is under no obligation to award a contract through competitive bidding, or at all.
  - 5. NHCC reserves the right to waive or extend deadlines.
  - 6. NHCC reserves the right to accept proposals in whole or part.
  - 7. NHCC reserves the right to conduct investigations with respect to the qualifications of each Proposer, to make field investigations with respect to such proposals (including visits to the Proposer's business offices or field operations).
  - 8. NHCC reserves the right to request additional information from any Proposer and to rely upon any information obtained through NHCC's own investigations.

- 9. NHCC reserves the right to cancel this RFP at any time whatsoever, with or without the substitution of another RFP.
- 10. NHCC reserves the right to supplement, amend or otherwise modify this RFP.
- 11. NHCC reserves the right to issue additional or subsequent RFPs with regard to the subject matter of this RFP.
- 12. NHCC reserves the right to negotiate with any Proposer, or with all or none of the Proposers. NHCC has no obligation to offer Proposers the opportunity to meet or exceed terms negotiated with a selected Proposer.
- 13. NHCC reserves the right to discontinue negotiations at any time and in NHCC's sole discretion.
- 14. NHCC reserves the right to request new or revised proposals, including monetary terms from any Proposer at any time.
- B. Preparation of a response to this RFP will be at the sole cost, expense and risk of the Proposer, with the express understanding and agreement of the Proposer, irrespective of whether it is selected, that it waives all claims whatsoever for reimbursement from NHCC for any cost or expense incurred in the preparation of its proposal and any subsequent contract negotiation.
- C. Each and every submitting Proposer expressly understands and agrees that this RFP is not, and shall not be construed as, an offer or an enforceable contract.
- D. NHCC intends to enter into contract negotiations with the Proposer or Proposers selected, who shall be required to enter into a written contract with NHCC in a form approved by Legal Counsel for NHCC. The contract usually includes, without limitation, the standard clauses set forth in Schedule "B" and Exhibit "JC" attached hereto. This RFP and the Proposal, or any part thereof, may be incorporated into and made a part of the contract. The contract may contain provisions not contained herein.

NHCC reserves the right to negotiate the terms and conditions of the contract with the selected Proposer(s), if any. These negotiations could include all aspects of services and fees. Neither the selection of a Proposer nor the negotiation of the contract with such Proposer(s) shall constitute NHCC's acceptance of a proposal or a binding commitment on behalf of NHCC to enter into a contract with such Proposer(s), as any binding arrangement must be set forth in the contract signed by both parties and is subject to all requisite approvals.

The contract, if any that is negotiated with a selected Proposer shall constitute the entire agreement between NHCC and the selected Proposer, and shall set forth all the terms and conditions applicable to the subject matter of this RFP. In the event of a conflict between this RFP and that contract, that contract shall control.

- E. No Proposer who has submitted a proposal to NHCC shall have the right to assign its submitted proposal to a third party or the right to enter into an agreement with third parties to perform the services on Proposer's behalf without the prior written consent of NHCC, which consent may be withheld in NHCC's sole discretion.
- F. This RFP shall be construed in accordance with and governed by the laws of the State of New York, without regard to conflicts of law principles. All actions or proceedings relating, directly or indirectly, to this RFP shall be litigated only in courts located within Nassau County or in the United States District Court for the Eastern District of New York. Each Proposer (by virtue of the submission of its proposal), submits itself, its successors and/or assigns (if any) to the personal jurisdiction of such court, and waives any right to trial by jury.
- G. The proposal shall be signed by an official authorized to bind the Proposer, and shall contain a statement to the effect that the proposal is a firm offer for a one hundred eighty (180) day (or more) period. The proposal shall also provide the name, title, address, and telephone number of the individual(s) with authority to negotiate and contractually bind the company, and who also may be contacted during the period of contract.
- H. Proposals submitted become the property of NHCC. By submitting a proposal, the Proposer agrees not to make any claims for or have any right to damages because of any misunderstanding, misrepresentation or lack of information.
- I. Ownership of any work developed under this order, and all right title and interest therein shall vest in NHCC. This includes any and all data sets and computer programs created for this analysis including any enhancements to existing data sets provided by NHCC. This includes any and all work materials, draft plans, preliminary analyses, and all other work materials created by the contractor for this contract. In order to effectuate the foregoing, it is expressly understood and acknowledged that the work shall be deemed to be a work made for hire under the U.S. copyright laws. In the event that the work is determined by a court or competent jurisdiction not to be a work made for hire under the U.S. copyright laws, all submissions to NHCC in connection with this RFP shall be deemed irrevocably assigned by the Proposer to NHCC, including, without limitation, the copyright in the work, including all right, title and interest in perpetuity.

### SCHEDULE "B" - STANDARD CLAUSES FOR NHCC CONTRACTS

NHCC reserves the right to add, subtract or modify clauses as it deems appropriate.

### Payments

- (a) <u>Vouchers; Voucher Review, Approval and Audit.</u> Payments shall be made to CONTRACTOR in arrears, subject to compliance with NHCC billing/payment procedures, and contingent upon CONTRACTOR submitting an invoice accompanied by documentation satisfactory to NHCC supporting the amount claimed.
- (b) <u>Timing of Payment Claims</u>. CONTRACTOR shall submit claims no later than three (3) months following the NHCC's receipt of the services that are the subject of the claim and no more frequently than once a month.
- (c) <u>No Duplication of Payments</u>. Payments under this Agreement shall not duplicate payments for any work performed or to be performed under other agreements between the CONTRACTOR and any funding source, including NHCC.
- (d) Payments in Connection with Termination or Notice of Termination. Unless a provision of this Appendix expressly states otherwise, payments to CONTRACTOR following the termination of this Agreement shall not exceed payments made as consideration for services that were (i) performed prior to termination, (ii) authorized by this Agreement to be performed, and (iii) not performed after CONTRACTOR received notice that the NHCC did not desire to receive such services.
- 2. <u>Independent Contractor.</u> CONTRACTOR is an independent contractor of the NHCC. CONTRACTOR shall not, nor shall any officer, director, employee, servant, agent or independent contractor of the CONTRACTOR (a "CONTRACTOR Agent"), be (i) deemed a employee of NHCC, (ii) commit NHCC to any obligation, or (iii) hold itself, himself, or herself out as an employee of NHCC or Person with the authority to commit the NHCC to any obligation. As used in this Agreement, the word "Person" means any individual person, entity (including partnerships, corporations and limited liability companies), and government or political subdivision thereof (including agencies, bureaus, offices and departments thereof).

### Compliance with Laws and NHCC Policies.

- (a) Generally. CONTRACTOR shall comply with any and all applicable Federal, State and local Laws, including, but not limited to those relating to conflicts of interest, identity theft, human rights, and disclosure of information, in connection with its performance under this Agreement. As used in this Agreement the word "Law" includes any and all statutes, local laws, ordinances, rules, regulations, applicable orders, and/or decrees, as the same may be amended from time to time, enacted, or adopted. In addition, CONTRACTOR shall follow all requirements of NHCC policies, procedures, quality assurance measures and performance improvement programs, including sentinel events/occurrences. Furthermore, CONTRACTOR shall maintain compliance with applicable standards of accreditation programs as required by NHCC, including, without limitation, The Joint Commission.
- (b) Records Access. The parties acknowledge and agree that all records, information, and data ("Information") acquired in connection with performance or administration of this Agreement shall be used and disclosed solely for the purpose of performance and administration of the contract or as required by law. CONTRACTOR acknowledges that CONTRACTOR Information in NHCC's possession may be subject to disclosure under Article 6 of the New York State Public Officer's Law ("Freedom of Information Law" or "FOIL"). In the event that such a request for disclosure is made, NHCC shall make reasonable efforts to notify CONTRACTOR of such request prior to disclosure of the Information so that CONTRACTOR may take such action as it deems appropriate.

- CONTRACTOR acknowledges and agrees that all Protection of Information. information that CONTRACTOR acquires in connection with performance under this Agreement shall be strictly confidential, used solely for the purpose of performing services to or on behalf of NHCC and shall not be disclosed to third parties except (i) as permitted under this Agreement, (ii) with the written consent of NHCC (and then only to the extent of the consent), or (iii) upon legal compulsion. In furtherance of the forgoing, CONTRACTOR and its employees, partners and agents shall keep the confidentiality of medical records and/or information including, but not limited to, HIV related information, relating to the care and treatment of NHCC patients, that may be obtained by CONTRACTOR in the performance of its duties hereunder, and shall maintain the confidentiality of all such records and information including, but not limited to, HIV related information, in conformity and consistent with applicable policies and standards of The Joint Commission, the confidentiality requirements of the New York State Public Health Law ("PHL") and the regulations promulgated thereunder, including, but not limited to, PHL Section 2782, and 10 NYCRR 415.22 and Parts 24 and 63 or as same may, from time-to-time, be amended as well as any other state and federal regulation regarding patient confidentiality, including, but not limited to, the regulations pursuant to the Health Insurance Portability and Accountability Act of 1996 ("HIPAA"). If applicable, CONTRACTOR further agrees to maintain and safeguard the confidentiality of health information relating to NHCC patients in accordance with the provisions a Business Associate Agreement. In the event of a breach by CONTRACTOR of this provision, NHCC may, at its option, terminate this Agreement immediately upon written notice to CONTRACTOR. The provisions of this paragraph shall survive this Agreement.
- (d) Patient Care/Contact. In the event that the services to be provided by CONTRACTOR or a CONTRACTOR Agent under this Agreement involve patient care or contact, CONTRACTOR acknowledges and agrees that all individuals performing such services shall: (i) be in good health and comply with all applicable health, immunization and infection control standards required of NHCC employees and (ii) be subject to successful completion of a background investigation substantially similar to those required of NHCC employees. CONTRACTOR represents and warrants that it is not aware of the existence of any facts or circumstances that indicate it would be inappropriate for such individuals to perform services under this Agreement. NHCC reserves the right to charge a CONTRACTOR a reasonable fee for costs associated with performing health services and/or background investigations necessary to ensure compliance with this paragraph.
- (e) NHCC Compliance Programs. CONTRACTOR agrees to adhere, and cooperate fully with, NHCC's corporate compliance program requirements applicable to all NHCC vendors, contractors, consultants and agents. This information is available via NHCC's website at: http://www.nuhealth.net/about/doing-business-with-nuhealth.asp
- (f) <u>Doing Business</u>. CONTRACTOR represents and warrants that: (a) it is properly licensed to do business in New York State and Nassau County, if applicable, (b) it is in good standing under such license(s), and (c) the activities conducted by it under such license(s) with respect to the services referenced above are in compliance with all requirements of the Laws governing such license(s). CONTRACTOR hereby agrees that it will continuously maintain (i) its existence and shall not dissolve or permit its dissolution, and (ii) its right to do business in New York State and Nassau County.
  - 4. <u>Minimum Service Standards</u>. Regardless of whether required by Law:
- (a) CONTRACTOR shall, and shall cause CONTRACTOR Agents to, conduct its, his or her activities in connection with this Agreement so as not to endanger or harm any Person or property.
- (b) CONTRACTOR shall deliver services under this Agreement in a professional manner consistent with the best practices of the industry in which the CONTRACTOR operates. CONTRACTOR shall take all actions necessary or appropriate to meet the obligations described in the immediately preceding sentence, including obtaining and maintaining, and causing all CONTRACTOR Agents to obtain and maintain, all approvals, licenses, and certifications ("Approvals") necessary or appropriate in connection with this Agreement.

### Indemnification; Defense; Cooperation.

- (a) CONTRACTOR shall be solely responsible for and shall indemnify and hold harmless NHCC and its officers, employees, and agents (the "Indemnified Parties") from and against any and all liabilities, losses, costs, expenses (including, without limitation, attorneys' fees and disbursements) and damages ("Losses"), arising out of or in connection with any acts or omissions of CONTRACTOR or a CONTRACTOR Agent, regardless of whether due to negligence, fault, or default, including Losses in connection with any threatened investigation, litigation or other proceeding or preparing a defense to or prosecuting the same; provided, however, that CONTRACTOR shall not be responsible for that portion, if any, of a Loss that is caused by the negligence of NHCC.
- (b) CONTRACTOR shall, upon the NHCC's demand and at the NHCC's direction, promptly and diligently defend, at CONTRACTOR'S own risk and expense, any and all suits, actions, or proceedings which may be brought or instituted against one or more Indemnified Parties for which CONTRACTOR is responsible under this Section, and, further to CONTRACTOR'S indemnification obligations, CONTRACTOR shall pay and satisfy any judgment, decree, loss or settlement in connection therewith.
- (c) CONTRACTOR shall, and shall cause CONTRACTOR Agents to, cooperate with NHCC in connection with the investigation, defense or prosecution of any action, suit or proceeding in connection with this Agreement, including the acts or omissions of CONTRACTOR and/or a CONTRACTOR Agent in connection with this Agreement.
  - (d) The provisions of this Section shall survive the termination of this Agreement.

### 6. Insurance.

- (a) Types and Amounts. CONTRACTOR shall obtain and maintain throughout the term of this Agreement, at its own expense: (i) one or more policies for commercial general liability insurance, which policy(ies) shall name "Nassau Health Care Corporation" as an additional insured and have a minimum single combined limit of liability of not less than One Million (\$1,000,000) Dollars per occurrence and Three Million (\$3,000,000) Dollars aggregate coverage, (ii) if contracting in whole or part to provide professional services, one or more policies for professional liability insurance, which policy(ies) shall have a minimum single combined limit liability of not less than One Million (\$1,000,000) Dollars per occurrence and Three Million (\$3,000,000) Dollars aggregate coverage, (iii) compensation insurance for the benefit of the CONTRACTOR'S employees ("Workers' Compensation Insurance"), which insurance is in compliance with the New York State Workers' Compensation Law, and (iv) such additional insurance as the NHCC may from time to time specify.
- (b) Acceptability; Deductibles; Subcontractors. All insurance obtained and maintained by CONTRACTOR pursuant to this Agreement shall be (i) written by one or more commercial insurance carriers licensed to do business in New York State and acceptable to NHCC, and which is (ii) in form and substance acceptable to NHCC. CONTRACTOR shall be solely responsible for the payment of all deductibles to which such policies are subject. CONTRACTOR shall require any subcontractor hired in connection with this Agreement to carry insurance with the same limits and provisions required to be carried by CONTRACTOR under this Agreement.
- (c) <u>Delivery: Coverage Change; No Inconsistent Action</u>. Prior to the execution of this Agreement, copies of current certificates of insurance evidencing the insurance coverage required by this Agreement shall be delivered to NHCC. Not less than thirty (30) days prior to the date of any expiration or renewal of, or actual, proposed or threatened reduction or cancellation of coverage under, any insurance required hereunder, CONTRACTOR shall provide written notice to NHCC of the same and deliver to NHCC renewal or replacement certificates of insurance. CONTRACTOR shall cause all insurance to remain in full force and effect throughout the term of this Agreement and shall not take or omit to take any action that would suspend or invalidate any of the required coverages. The failure of CONTRACTOR to maintain Workers' Compensation Insurance shall render this contract void and of no effect. The failure of

CONTRACTOR to maintain the other required coverages shall be deemed a material breach of this Agreement upon which the NHCC reserves the right to consider this Agreement terminated as of the date of such failure.

- 7. <u>No Arrears or Default.</u> CONTRACTOR represents and warrants that it is not in arrears to NHCC upon any debt or contract and it is not in default as surety, contractor, or otherwise upon any obligation to NHCC, including any obligation perform services for or on behalf of NHCC.
- 8. <u>Assignment; Amendment; Waiver: Subcontracting</u>. This Agreement and the rights and obligations hereunder may not be in whole or part (i) assigned, transferred or disposed of, (ii) amended, (iii) waived, or (iv) subcontracted, without the prior written consent of the President of NHCC his or her duly designated representative (the "President"), and any purported assignment, other disposal or modification without such prior written consent shall be null and void. The failure of a party to assert any of its rights under this Agreement, including the right to demand strict performance, shall not constitute a waiver of such rights.

### 9. Termination.

(a) Generally. This Agreement may be terminated (i) by NHCC, for any or no reason, upon thirty (30) days written notice to CONTRACTOR, (ii) for "Cause" by NHCC immediately upon the receipt by CONTRACTOR of written notice of termination, (iii) upon mutual written Agreement of NHCC and CONTRACTOR, and (iv) in accordance with any other provisions of this Agreement expressly addressing termination.

As used in this Attachment the word "Cause" includes: (i) a breach of this Agreement; (ii) the failure to obtain and maintain in full force and effect all Approvals required for the services described in this Agreement to be legally and professionally rendered; and (iii) the termination or impending termination of federal or state funding for the services to be provided under this Agreement.

- (b) By CONTRACTOR. This Agreement may be terminated by CONTRACTOR if performance becomes impracticable through no fault of CONTRACTOR, where the impracticability relates to the CONTRACTOR'S ability to perform its obligations and not to a judgment as to convenience or the desirability of continued performance. Termination under this subsection shall be effected by CONTRACTOR delivering to President, at least sixty (60) days prior to the termination date (or a shorter period if sixty (60) days notice is impossible), a notice stating (i) that CONTRACTOR is terminating this Agreement in accordance with this subsection, (ii) the date as of which this Agreement will terminate, and (iii) the facts giving rise to CONTRACTOR'S right to terminate under this subsection. A copy of the notice given to the President shall be given to the NHCC department head who oversees the administration of this Agreement on the same day that notice is given to the President.
- (c) <u>CONTRACTOR Assistance upon Termination</u>. In connection with the termination or impending termination of this Agreement, CONTRACTOR shall, regardless of the reason for termination, take all actions reasonably requested by NHCC (including those set forth in other provisions of this Agreement) to assist NHCC in transitioning CONTRACTOR 's responsibilities under this Agreement. The provisions of this subsection shall survive the termination of this Agreement.
- 10. Records Access and Retention. CONTRACTOR, including its satellites, offices and/or subcontractors, if any, shall maintain full and complete books and records of accounts specifically pertaining to this Agreement, in accordance with accepted accounting practices and such other records as may be reasonably prescribed by NHCC and the New York State Comptroller. Such books and records shall at all times be available for audit and inspection by the State Comptroller, or a duly designated representative, or by NHCC. All such books and records shall be retained for a period of six (6) years after the completion of all the services described in this Agreement. CONTRACTOR further agrees that if any provision of Section 952 of the Omnibus Reconciliation Act of 1980 (PL-96-499) is found by a body of competent jurisdiction to be applicable to this Agreement, CONTRACTOR will make available upon written request by the Secretary of Health & Human Services, or by the Comptroller General of the General

Accounting Office, or any of their duly authorized representatives, a copy of this Agreement and any executed amendments thereto, documents which relate to the calculation of the charges in the Agreement and copies of service reports documenting services performed. Such records will be available in accordance with the above for a period of six (6) years after the furnishing of any of the services described in this Agreement.

11. <u>Work Performance Liability</u>. CONTRACTOR is and shall remain primarily liable for the successful completion of all work in accordance this Agreement irrespective of whether CONTRACTOR is using a CONTRACTOR Agent to perform some or all of the work contemplated by this Agreement, and irrespective of whether the use of such CONTRACTOR Agent has been approved by NHCC.

### Consent to Jurisdiction and Venue; Governing Law, Jury Trial Waiver.

- (a) Unless otherwise required by Law, exclusive original jurisdiction for all claims or actions with respect to this Agreement shall be in the Supreme Court in Nassau County in New York State and the parties expressly waive any objections to the same on any grounds, including venue and <u>forum non conveniens</u>. This Agreement is intended as a contract under, and shall be governed and construed in accordance with, the Laws of New York State, without regard to the conflict of laws provisions thereof.
- (b) THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVE ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT
- 13. <u>No Exclusions</u>. CONTRACTOR warrants that neither it nor any of its officers, employees or agents is excluded from doing business with any federal, state or local agency, municipality or department. Any misrepresentation or false statement regarding CONTRACTOR'S status shall result in immediate termination of this Agreement.
  - 14. Executory Clause. Notwithstanding any other provision of this Agreement:
- (a) <u>Approval and Execution</u>. NHCC shall have no liability under this Agreement (including any extension or other modification of this Agreement) to any Person unless (<u>i</u>) all NHCC approvals have been obtained, including, if required, approval by the NHCC Board of Directors, and (<u>ii</u>) this Agreement has been executed by the President.
- (b) Availability of Funds. NHCC have no liability under this Agreement (including any extension or other modification of this Agreement) to any Person beyond funds appropriated or otherwise lawfully available for this Agreement, and, if any portion of the funds for this Agreement are from the state and/or federal governments, then beyond funds available to NHCC from the state and/or federal governments.

### Exhibit - "JC"

# JOINT COMMISSION STANDARDS FOR CONTRACTORS, VENDORS AND VOLUNTEERS

All contractor, subcontractor, vendor, and volunteer personnel (collectively, "Staff"), regardless of their level of interaction with patients, shall participate in NuHealth New Employee Orientation, applicable Departmental Orientation(s) and be held to the same standards as regular NuHealth employees. Additionally, all Staff providing patient care or services must adhere to the requirements outlined below:

### Patient Care/Services Staff

- Patient care Staff include, but are not limited to: nursing, therapy, dietary, pharmacy, activities staff, drug and alcohol counselors such as AA counselors, and nursing assistants/aides.
- <u>Patient services Staff</u> include, but are not limited to: homemakers, sitters, companions, chore workers, drivers, home medical equipment delivery and repair technicians, volunteers transporting patients.

### Non Patient Care/Services Staff

• Non-patient care or service Staff include, but are not limited to: volunteers who deliver the mail or flowers, staff the information desk, gift shop or library services, perform patient errands (e.g. writing and mailing letters or obtaining magazines and toiletries from the gift shop), conduct marketing or fund raising activities.

### Information Required for all Patient Care/Services Staff

- Education and training that is consistent with applicable legal and regulatory requirements;
- Copy of license, certification, or registration when applicable;
- Documentation, such as a curriculum vitae, that individual's knowledge and experience and competence are appropriate for his or her assigned responsibilities;
- Performance evaluations from appropriate NuHealth personnel;
- Pre-employment physical exam and annual health assessments;
- Pre-employment verification of convictions for abuse or neglect;
- Successful completion of a background investigation acceptable to NHCC;
- If assigned to work with children, Staff must be cleared by the NY Statewide Central Registry; and
- References, when applicable.

Except as set forth below, supporting documentation must be submitted to Yuliis Perea in Human Resources. Staff credentialed through the NHCC Medical Staff Office shall be deemed to have satisfied the above requirements as part of the NHCC credentialing process.

# APPENDIX I

### Statement of non-collusion in bids or proposals to Public Authority

By submission of this bid, each bidder and each person signing on behalf of any bidder certifies, and in the case of a joint bid each party thereto certifies as to its own organization, under penalty of perjury, that to the best of his knowledge and belief:

- (1) The prices in this bid have been arrived at independently without collusion, consultation, communication, or agreement, for the purpose of restricting competition, as to any matter relating to such prices with any other bidder or with any competitor;
- (2) Unless otherwise required by law, the prices which have been quoted in this bid have not been knowingly disclosed by the bidder and will not knowingly be disclosed by the bidder prior to opening, directly or indirectly, to any other bidder or to any competitor; and
- (3) No attempt has been made or will be made by the bidder to induce any other person, partnership or corporation to submit or not to submit a bid for the purpose of restricting competition.

# SUBSCRIBED TO UNDER PENALTY OF PERJURY UNDER THE LAWS OF THE STATE OF NEW YORK:

Entity submitting bid/proposal:	
Signature of Principal or Corporate Officer:	
Printed Name:	
Title:	
Date:	-

# **Disclosure of Contacts Form**

Name of Contractor:
Address:
Name and Title of Person Submitting this Form:
Is this an initial filing in accordance or an updated filing? (Please circle one):
Initial filing Updated filing
The following person or organization was retained, employed or designated by or on behalf of the Contractor to attempt to influence the procurement process:
Name:
Address:
Telephone Number:
Place of Principal Employment:
Occupation:
Does the above-named person or organization have a financial interest in the procurement?
(Please circle one) yes no

# Disclosure of Prior Non-Responsibility Determinations Form

Name of Contractor:	
Address:	
Name and Title of Person Submitting this Form:	
Has any covered agency or authority made a finding of non-responsibility regarding the Contractor in the last five years? (Please circle one):	
No Yes	
If yes, was the basis for the finding of the Contractor's non-responsibility due to the intention provision of false or incomplete information? (Please circle one):	ional
No Yes	
If yes, please provide details regarding the finding of non-responsibility below.	
Covered Agency or Authority:	
Year of Finding of Non-responsibility:	
Basis of Finding of Non-Responsibility:	
· · · · · · · · · · · · · · · · · · ·	
Has any covered agency or authority terminated a procurement contract with the Contractor to the intentional provision of false or incomplete information? (Please circle one):	or due
No Yes	

# M/WBE UTILIZATION PLAN

rd. This Utilization Plan must contain a additional sheets if necessary.		KFF or Bid No.  M/WBE Goals in the Contract: MBE % WBE %  EEO Goals in the Contract: MBE % WBE %  (If no Goals listed above or in RFP, Goal is 20% Total through any combination)	5. Dollar Value of Subcontracts/ Supplies/Services and intended performance dates of each component of the contract.				
negotiated contract or within a reasonable time thereafter, but prior to contract award. This Utilization Plan must contain a nority and Women-owned Business Enterprise (M/WBE) under the contract. Attach additional sheets if necessary.	Federal Identification No.: Location of Work:	KFF or Bid No.  M/WBE Goals in the Contract: MBE  EEO Goals in the Contract: MBE  (If no Goals listed above or in RFP, Goa	4. Detailed Description of Work (Attach additional sheets, if necessary)			*:	
contract or within a reaso Vomen-owned Business E			3. Federal ID No.				
oposal, or proposed negotiated by each certified Minority and V			2. Classification	NYS ESD CERTIFIED  MBE  WBE	NYS ESD CERTIFIED  MBE  WBE	NYS ESD CERTIFIED  MBE  WBE	NYS ESD CERTIFIED    MBE   WBE
NSTRUCTIONS: This form must be submitted with any bid, proposed negotiated contract or within a reasonable time thereafter, but prior to contract award. This Utilization Plan must be etailed description of the supplies and/or services to be provided by each certified Minority and Women-owned Business Enterprise (M/WBE) under the contract. Attach additional sheets if necessary	Offeror's Name:	elephone No.: Email Address:	1. Certified M/WBE Subcontractors/Suppliers Name, Address, Email Address, Telephone No.	-	2.	3,	4.

5.	NYS ESD CERTIFIED  ☐ MBE  ☐ WBE	
9	NYS ESD CERTIFIED  MBE	
7.	NYS ESD CERTIFIED    MBE   WBE	
8	NYS ESD CERTIFIED  MBE	
6	NYS ESD CERTIFIED  MBE	
6. IF UNABLE TO FULLY MEET THE MBE AND WBE GOALS SET FOR PREPARED BY (Signature):  DATE:  NAME AND TITLE OF PREPARER: SUBMISSION OF THIS FORM CONSTITUTES THE OFFEROR'S ACKNOWLEDGIARTICLE 15-A, 5 NYCRR PART 143, AND THE ABOVE-REFERENCED SOIN NONCOMPLIANCE AND POSSIBLE TERMINATION OF YOUR CONTRACT.	BE GOALS SET FORTH IN THE SET SET FORTH IN THE SET SET FORTH IN THE SET SET FORTH AN THE SET SET SET SET SET SET SET SET SET SE	6. IF UNABLE TO FULLY MEET THE MBE AND WBE GOALS SET FORTH IN THE RFP, OFFEROR MAY REQUEST A WAIVER OF MWBE PARTICIPATION  PREPARED BY (Signature):  DATE:  NAME AND TITLE OF PREPARER:  SUBMISSION OF THIS FORM CONSTITUTES THE OFFEROR'S ACKNOWLEDGEMENT AND AGREEMENT TO COMPLY WITH THE M/WBE REQUIREMENTS SET FORTH UNDER NYS EXECUTIVE LAW, ARTICLE 15-A, 5 NYCRR PART 143, AND THE ABOVE-REFERENCED SOLICITATION. FAILURE TO SUBMIT COMPLETE AND ACCURATE INFORMATION MAY RESULT IN A FINDING OF NONCOMPLIANCE AND POSSIBLE TERMINATION OF YOUR CONTRACT.

RFP 2018 - 009 Attachment 1 - LABORATORY

		Anticipated Annual			
Test Name	CPT	Volume	Turn around Time (indicate hours/days)	Price	Performing Lab
10-HYDROXYCARBAZEPINE	80183	57			
14-3-3 PROTEIN,CSF	83520	1			
17-HYDROXYPROGESTERONE	83498	113			
17-OH-PREGNENOLONE, SERUM	84143	3			
5-FLUOROCYTOSINE, HPLC	83789	1			
5-HIAA,24HR URINE	83497	7			
A ACID ANAL, LC/MS, (P), NY	82139	4			
A. PULLULANS (M12) IGE	86003	1			
A.PHAGOCY+E.CHAFFEE AB PL	PROFILE	1			
A1-ANTITRYPSIN, RAND FECES	82103	1			
ACETONE, SERUM	82010	5			
ACETYLCHOLINE REC BLOCKIN	83519	18			
ACETYLCHOLINE RECEP BINDI	83519	15			
ACETYLCHOLINE RECEP MODUL	83519	14			
ACTH, PLASMA	82024	191			
ADENOSINE DEAM, PERITONEAL	84311	1			
ADENOSINE DEAMIN, PLEURAL	84311	40			
ADENOVIRUS AB	86603	2			
ADENOVIRUS AB, CF (CSF)	86603	3			
ADRENAL AB W/RFX	86255, PROFILE	7			
AFP, AMNIOTIC FL W/RFX, NY	PROF	19			
AFP, PLEURAL FLUID	86316	1			
AFP, TUMOR MARKER, SERUM	82105	472			
ALBUMIN, PERITONEAL FLUID	82042	42			
ALBUMIN, PLEURAL FLUID	82042	12			
ALBUMIN, CSF	82042, 83883	1			
ALCOHOL, METHYL, BLOOD	80320	10			
ALDER (T2) IGE	86003	1			
ALDOLASE	82085	43			
ALDOSTERONE, SERUM	82088	55			
ALDOSTERONE, URINE	82088	9			
ALK PHOSPHATASE ISOENZYME	PROFILE	80			
ALK PHOSPHATASE, BONE	84075	2			
ALLERG, IGE HICKORY WHITE	86003	6			
ALLERGEN (IGE), BLACK BEA	86003	1			
ALLERGEN (IRE)CUMIN SEED	86003	1			
ALLERGEN IGE TILAPIA	86003	1			
ALLERGEN, CHESTNUT	86003	3			
ALLERGEN, HOUSE DUST, GREER	86003	3			
ALLLERGEN CORIANDER/CILAN	86003	1			
ALMOND (F20) IGE	86003	7			
	44.41	7			

RFP 2018 - 009 Attachment 1 - LABORATORY

		nancipared .			
Test Name	CPT	Annual	Turn around Time (indicate hours/days)	Price	Performing Lab
ALPHA SUBUNIT	82397	17			
ALPHA THALASSEMIA, DNA NY	81257	10			
ALPHA-1-ANTITRYPSIN	82103	174			
ALPHA-1-ANTITRYPSIN PHENO	PROFILE	25			
ALPHA-FETOPROTEIN, CSF	86316	2			
ALPRAZOLAM	80346	2			
ALTERNARIA TENUIS (M6) IG	86003	54			
AMINO ACIDS,URINE NY	PROFILE	1			
AMIODARONE & METABOLITE	80299	,			
AMITRIPTYLINE & NORTRIPTY	80152, 80335	3			
AMOXAPINE AND METABOLITE	80335	1			
AMPHETAMINE, CONF, GCMS, SER	80324	,			
AMYLASE ISOENZYMES, SERUM	PROFILE	2			
ANA TITER		123			
ANACHOICE SCR		705			
ANCA/VASCULITIDES	86021	168			
ANDROSTENEDIONE, LC/MS/MS	82157	49			
ANGIOTENSIN CONV ENZY, CSF	82164	2			
ANGIOTENSIN CONVERTING EN	82164	91			
ANTI-68 KD (HSP-70) ANTIB	84181	-			
ANTI-CARDIOLIPIN IGG	86147	283			
ANTI-CARDIOLIPIN IGM	86147	281			
ANTI-MULLERIAN HORMONE AS	82397	69			
ANTI-THROMBIN III, ANTIGEN	85301	25			
ANTI-THROMBIN III, FUNCTIO	85300	65			
APOLIPOPROTEIN A-1&B	82172	1			
APPLE (F49) IGE	86003	4			
AQUAPORIN-4 (AQP4) AB,CBA	86255	-			
ARGININE VASOPRESSIN	84588	4			
ARIPIPRAZOLE SER/PLAS	80299	~			
ARSENIC, BLOOD	82175	69			
ASPERGILLUS AB, ID	86606	13			
ASPERGILLUS AG, EIA, BAL	87305	4			
ASPERGILLUS ANTIGEN	87305	7			
ASPERGILLUS FLAVUS IGE	86003	2			
ASPERGILLUS FUMIGATUS (M3	86003	62			
ASPERGILLUS NIGER (M207)	86003	2			
AVOCADO (F96) IGE	86003	1			
B. BURGDORFERI AB INDEX	PROF				
B. BURGDORFERI G & M WB C	PROF	38			
B. HENSELAE IGG TITER	86611	2			
OTTIT OU AMATINITO O	86611	•			

RFP 2018 - 009 Attachment 1 - LABORATORY

CPT   Voll   GG/WB   86617   Voll   GG/M), 86617   16   GG/M), 86617   16   GMI),WB   86617   16   FA CSF   PROF   16   SMIJIFA   87738   4   SET DNA			Anticipated Annual			
86617 86617 86618 86618 86618 86753 86753 87798 87798 86003	Test Name	CPT	Volume	Turn around Time (indicate hours/days)	Price	Performing Lab
86617 86618 86618 86618 86753 86753 87798 83520, 86146 82232 86003	B.BURGDORFERI AB (IGG),WB	86617	7			
86617       86618       86753       87798       87798       82232       86003       8603       8603       8603       8603       8603       8603       8603       8603       8603       8603       8603       8603       8603       86	B.BURGDORFERI AB (IGG,M),	86617	165			
86618       PROF       86753       87798       87798       82232       86003       8603       8603       8603       8603       8603       8603       8603       8603       8603       8603       8603       8603       8603       860	B.BURGDORFERI AB (IGM), WB	86617	7			
PROF  86753  A 87798  87798  83520, 86146  86003	B.BURGDORFERI AB SCREEN W	86618	873			
A 86753  A 87798  83520, 86146  1 86003  86003	B.BURGDORFERI AB, IFA CSF	PROF	2			
A 87798  83520, 86146  8 8232  8 6003	B.MICROTI AB (IGG, IGM)IFA	86753	3			
83520, 86146  82232 86003	B.PERTUSSIS/PARAPERT DNA	87798	4			
MAT   82232   86003	B2 GLYCOPROTEIN I (IGG,A)	83520, 86146	208			
86003           86003 </td <td>B2 MICROGLOBULIN, SERUM</td> <td>82232</td> <td>17</td> <td></td> <td></td> <td></td>	B2 MICROGLOBULIN, SERUM	82232	17			
86003   8600	BAHIA GRASS (G17) IGE	86003	1			
86003   8600	BANANA (F92) IGE	86003	10			
Se003   Se00	BARLEY (F6) IGE	86003	3			
SEGO3   SEGO	BASIC METABOLIC PANEL		5			
DAN PCR   PROFILE   86003   86003   86003   86003   86003   86003   86003   86003   86003   86003   86003   86003   86003   87799   87799   86003	BASIL (F269) IGE	86003	1			
86003 86003 86003 86003 86003 84600 84600 84600 86003 82232 82324 82374 82374 82374 82422 86003	BCR-ABL1 GENE, QN PCR	PROFILE	30			
SEGO3   SEGO	BEECH (TS) IGE	86003	29			
SEGO3   SEGO	BEEF (F27) IGE	86003	ιΩ			
84600 86003 82010 86008 86335 82232 82232 80003 87799 86003 86612 86612 86612 86603	BEET IGE	86003	-			
86003 86335 86335 86335 82232 82232 86003 86003 86003 86612 86612 86603	BENZENE	84600	94			
82010 86008 86335 86335 8232 8232 82033 86003 86003 86612 86612 86603 86603 86603 86603 86603 86603 86603 86603 86603 86603 87398 86603 86603 87348	BERMUDA GRASS (G2) IGE	86003	12			
86008       86335       8232       82374       82542       86003	BETA HYDROXYBUTYRATE	82010	2			
86335 8232 8232 8234 82542 86003 86003 86003 86612 86612 86603 86003 86003 86003 86003 86003 86003 86003 86003 87380 86003 873880 873880 873880 873880	BETA LACTALBUMIN (F77) IG	86008	2			
82232 82374 82542 86003 86003 86003 86612 86612 86612 86603 86603 86003 8003 8	BETA-2,TRANSFERRIN,(BF)	86335	1			
82374 82542 86003 86003 86003 86612 86612 86612 86612 86612 86612 86603 86003	BETA-2-MICROGLOBULIN,CSF	82232	1			
82542 86003 87799 86003 86003 86612 86612 86612 86603 86003	BICARBONATE, URINE	82374	-			
86003 87799 86003 86003 86612 86612 86603 86003	BILE ACIDS FRACTIONATED	82542	78			
86003 86003 86003 86612 86612 86003 86003 86003 N 86622 D B 8380 GG 8380 B603 R6622 N 86622 N 86622 B 8038 R603 R603 R603 R603 R603 R603 R603 R603	BIRCH (T3) IGE	86003	88			
86003 86003 86612 86612 86003 86003 86003 94 86003 1D 83880 1GG 83520 1GG 83520 MA 80338 MA 80338	BK VIRUS DNA QUANT PCR	87799	22			
86612 86612 86612 86003 86003 86003 A B 86003 ID 86602 IG 83520 IG 83520 IG 83520 IG 83520 IG 80348 MA 80338	BLACK PEPPER (F280) IGE	86003	2			
86612 86612 86003 86003 86003 AA 86622 ID 83880 IGG 83520 IE 80348 MA 80338	BLACKBERRY (F211) IGE	86003	-			
86612   86003   86003   86003   86003   86003   86003   86003   86003   86003   86003   86003   86003   86003   86003   80348   80338   803345	BLASTOMYCES AB,CF (CSF)	86612	-			
86003 86003 86003 86003 EPTID 86622 EPTID 86603 230 IGG 83520 JRINE 80348 LASMA 80338	BLASTOMYCES AB,ID	86612	က			
86003 86003 86622 83880 86003 66 83520 80348 A 80338	BLUEBERRY (F288) IGE	86003	3			
86622 86622 83880 86003 66 83520 80348 A 80338	BRAZIL NUT (F18) IGE	86003	8			
86622 83880 86003 66 83520 80348 A 80338	BROCCOLI (F260) IGE	86003	1			
83880   86003   83520   80348   A   80338	BRUCELLA AB (IGG, IGM) EIA	86622	1			
230 IGG 83520 RINE 80348 ASMA 80338	B-TYPE NATRIURETIC PEPTID	83880	1			
83520 80348 80338 803345	BUCKWHEAT (F11) IGE	86003	1			
80348 80338 80345	BULLOUS PEMPHIG BP230 IGG	83520	-			
80338	BUPRENORPHINE, QN, URINE	80348	1			
80345	BUPROPION, SERUM/PLASMA	80338	-			
2	BUTALBITAL SERUM	80345	-			

RFP 2018 - 009 Attachment 1 - LABORATORY

PA	Test Name	CPT	Anticipated Annual Volume	Turn around Time (indicate hours/days)	Price	Performing Lab
RASE INHIBITOR, FUN         86160, 86161           RASE INHIBITOR, TOT         86160, 86161           UM         86160           IM         86160           IM         86160           IM         86160           IM         86160           IM         86160           IM         86304           86304         86316           86307         86316           86307         86316           90         86300           10IN         82300           10IN         82300           10IN         82300           10IN         82300           10IN         81219           RALBICANS AB, ID         86628           CULIN MUTATION         81219           RALBICANS AB, ID         86628           CUDFE IGG         86003           RALBICANS AB, ID         86628           CUDFE IGG         86003           ROLD IGE         86003           AND IGE         86003           RATH DISEASE AB PA         82384           ROLD AMINE, FRAC, PLASM         82384           NE PEPPER IGE         86003           RICARDAL FLUID <th< td=""><td>C.TRACH/N.GON RNA TMA REC</td><td>PROFILE</td><td>15</td><td></td><td></td><td></td></th<>	C.TRACH/N.GON RNA TMA REC	PROFILE	15			
REASE INHIBITOR, TOT   RE160, RE161	C1 ESTERASE INHIBITOR, FUN	86160, 86161	19			
Mail	C1 ESTERASE INHIBITOR, TOT	86160, 86161	20			
Miles   86160	C1Q,SERUM	86160	9			
86304   86304   86306   86300   86300   86300   86300   86300   86300   86300   86300   86300   80300   80300   80300   80300   80300   80300   80300   80300   80300   80300   80300   80300   80300   80300   80001   80002   80001   80003   8000	C2,SERUM	86160	3			
96300           98301         86306           9         86301         86316           9         86301         86316           9         86300         86316           100         82300         86316           100         82300         86316           10         82300         86316           10         82300         82330           10         82330         82330           10         86628         8601           10         86141         86141           10         86141         86147           10         86147         86147           10         86147         86147           10         86147         86147           10         86147         86147           10         86147         86147           10         86147         86147           10         86147         86147           10         86147         86147           10         86147         86147           10         86147         86147           10         86147         86147           10         86147         86147	CA 125	86304	179			
B6301, 86316	CA 15-3	86300	12			
86300, 86316 82300 0M 82330 0N 82330 0N 81219 86028 96001 86147 86147 86147 86147 86147 86147 86147 86147 86147 86147 86147 86148 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 85025 UID 82378 86003 85025 UID 82378 86003 85025 UID 82378 86003 85025 UID 82378 86003 85026 UID 82390	CA 19-9	86301, 86316	164			
82300  82308  ON  82330  ON  82330  ON  81219  ON  86628  Se001  86147  86147  86147  86147  86003  Se003	CA 27.29	86300, 86316	17			
10   10   10   10   10   10   10   10	CADMIUM, BLOOD	82300	91			
ON 82330  83993 ON 81219  86628 86001 86147 86147 86147 86147 86379 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 85025 UID 89051 UID 89051 UID 82390	CALCITONIN	82308	47			
83993   83993   81219   81220   86028   86011   86147   86147   86147   86147   86003   8600	CALCIUM, IONIZED, SERUM	82330	1			
ON 81219 86628 86001 86147 86147 86147 86147 82379 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 85025 UID 89051 UID 89050 UID 82390	CALPORTECTIN, STOOL	83993	3			
86628   86001   86141   86141   86147   82379   86003   86003   86003   86003   86003   86003   82384   82384   82384   82384   82384   82384   82384   82378   86003   82378   82378   82390   8239	CALRETICULIN MUTATION	81219	4			
86001         86001           86147         86147           86003         86003           3E         86003           3E         86003           3E         86003           4C,PLASM         82384           4C,PLASM         82384           4C,PLASM         82384           BOOT         82378           BOOT         89051           NOVIA         PROFILE           LUID         89050           CV SCR         81220           RP SCR         81220           RP SCR         81200           85) IG         86003           REFLEX         86790           REFLEX         86790	CANDIDA ALBICANS AB, ID	86628	5			
86141           86147           86147           82379           86003           86003           AB PA         86003           86003         86003           C.W/O CR         82384           AC,PLASM         82384           AC,PLASM         82384           BO OT         82036           LUID         82378           DOT         89051           NOVIA         PROFILE           LUID         82390           KP SCR         81220           RP SCR         81220           RP SCR         81200           85) IG         86003           85) IG         86003           85) IG         86003           REFLEX         86790           RRFLEX         86730	CANTALOUPE IGG	86001	1			
86147   82379   82003   86003   86003   86003   86003   86003   86003   86003   86003   86003   86003   82384   86003   82384   86003   82378   80001   82378   80001   82050   82050   82050   82050   82050   82050   82050   820003   82	CARDIO CRP	86141	1			
82379 86003 3E 86003 3E 86003 3AB PA 86255,86611 CW/O CR 82284 AC,PLASM 82284 AC,PLASM 86003 85025 (blank) IID 82378 BOOT R9051 NOVIA PROFILE LUID 82390 CP SCR 81220 1) IGE 86003 82) IG 86003 85) IG 86003 86003 87) IG 86003 86003 87) IG 86003 88) IG 86003 88) IG 86003 88) IG 86003 88) IG 86003	CARDIOLIPIN AB IGA	86147	228			
86003 86003 86003 86003 86003 86003 82384 82384 82384 86003 82025 (blank) 82378 82378 10 89051 10 82390 5CR 81220 6E 86003 11G 86003	CARNITINE, LC/MS/MS	82379	6			
86008 86003 86003 86003 86003 87005 87284 87286 87286 87286 87280	CARROT (F31) IGE	86003	2			
86003 8 PA 8 86255, 86611 W/O CR 8 22384 PLASM 82384 86003 86003 86003 85025 (blank) 82378 0)T 89051 N/A PROFILE 1D 82390 SCR 81220 GE 86003 ) IG 86003 ) IG 86003	CASEIN (F78) IGE	86008	6			
EAB PA EAB PA EAB PA EAB PA EAC, PLASM E2384  AC, PLASM E2384  E6003 E6003 E6003 E6003 E7000 E70	CASHEW NUT (F202) IGE	86003	5			
8655, 86611 82384 82384 86003 85025 (blank) 82378 89051 PROFILE 89050 81220 81220 81220 82390 81220 86003 86003 86003 86003	CAT DANDER (E1) IGE	86003	37			
82384 82384 86003 86003 85025 (blank) 82378 89051 PROFILE 89050 872390 87230 86003 86003 86003 86003 86003	CAT SCRATCH DISEASE AB PA		13			
82384 86003 85025 (blank) 82378 89051 PROFILE 89050 872390 87220 86003 86003 86003 86003 86003 86003	CATECHOLAMINE, FRAC W/O CR	82384	19			
86003 85025 (blank) 82378 89051 PROFILE 89050 82390 81220 82390 81220 86003 86003 86003 86003 86003	CATECHOLAMINES, FRAC, PLASM	82384	20			
85025 (blank) 82378 82051 PROFILE 89050 82390 81220 82390 81220 86003 86003 86003 86003 86003 86003 86003	CAYENNE PEPPER IGE	86003				
(blank) 82378 82051 89051 PROFILE 89050 82390 81220 86003 86003 86003 86003 86003 86003 86003	CBC W/ DIFF & PLT	85025	14			
82378 89051 PROFILE 89050 82390 81220 86003 86003 86003 86003 86003 86003 86003	CBC W/ DIFF & PLT	(blank)	-			
89051 PROFILE 89050 82390 81220 86003 86003 86003 86003 86003 86003	CEA, PERICARDIAL FLUID	82378	-			
PROFILE 89050 82390 81220 86003 86003 86003 86003 66003	CELL CNT & DIFF, FLUID OT	89051	80			
89050 82390 81220 86003 86003 86003 86003 86003 86790	CELL CNT AND DIFF, SYNOVIA	PROFILE	~			
82390 81220 86003 86003 86003 86003 \$6003 \$6790	CELL COUNT W/DIFF, FLUID	89050	4			
81220 86003 86003 86003 86003 86003 \$ 86790 \$ 86790	CERULOPLASMIN	82390	239			
86003 86003 86003 86003 86003 46790	CFVANTAGE(TM) CF EXP SCR	81220	-			
86003 86003 86003 X 86790	CHEDDAR CHEESE (F81) IGE	86003	2			
86003 86003 X 86790	CHEESE MOLD TYPE (F82) IG	86003	1			
86003 86003 X 86790	CHERRY (F242) IGE	86003	1			
x 86790	CHICKEN FEATHERS (E85) IG	86003	2			
86790	CHICKEN MEAT (F83) IGE	86003	2			
86790	CHIKUNGUNYA AB W/REFLEX	86790	ю			
06.00	CHIKUNGUNYA IGG TITER	86790	2			

RFP 2018 - 009 Attachment 1 - LABORATORY

		Anticipated Annual			
Test Name	CPT	Volume	Turn around Time (indicate hours/days)	Price	Performing Lab
CHILDHOOD ALLERGY PROFILE	PROFILE	-			
CHILI PEPPER (F279) IGE	86003	n			
CHLAMYDIA AB (IGG,IGA,IGM	PROFILE	2			
CHLAMYDIA SPECIES AB (IGG	86631	-			
CHOCOLATE (F93) IGE	86003	8			
CHOLESTEROL PLEURAL FLUID	84311	3			
CHOLINESTERASE, PLASMA	82480	1			
CHROMOGRANIN A	86316	32			
CHROMOGRANIN A, SERUM	86316	8			
CHROMOSOMES, AMNIOTIC FLUI	PROF	1			
CHROMOSOMES, BLOOD	PROF	40			
CHROMOSOMES, HEMATOLOGIC	PROF	34			
CHROMOSOMES, HIGH RESOLUTI	PROF	က			
CHROMOSOMES, TISSUE	PROF	9			
CLADOSPORIUM HERBARUM (M2	86003	13			
CLAM (F207) IGE	86003	3			
CLL PROGNOSTIC PANEL COMP	PROFILE	က			
CLOBAZAM	80346	-			
CLONAZEPAM,SERUM	80154, 80346	8			
CLOSTRIDIUM DIF TOXIN B,Q	87493	164			
CLOZAPINE	80159	143			
CMV AB (IGG)	86644	72			
CMV DNA Q1 REAL TIME PCR	87496	5			
CMV DNA,QN,REAL-TIME PCR	87497	58			
COCA!NE,CONFIRMATION,GCMS	80353	-			
COCCIDIOIDES AB,ID	86635	15			
COCKLEBUR (W13) IGE	86003	2			
COCKROACH (16) IGE	86003	35			
COCONUT (F36) IGE	86003	4			
CODFISH (F3) IGE	86003	2			
COLD HEMAGGLUTINATION	86157	2			
COLLAGEN CROSS-LINKED, UR	82523	-			
COMMON RAGWEED (W1) IGE	86003	76			
COMP METABOLIC PANEL	80053	12			
COMPLEMENT, TOTAL (CH50)	86162	15			
COPPER,24HR URINE	82525	9			
COPPER, SERUM	82525	35			
CORN (F8) IGE	86003	00			
CORTISOL, FREE, LC/MS/MS	82530	21			
COUMADIN, PLASMA	80299	2			
COXSACKIE A AB (2,4,7,9,1	86658	თ			
	00000	cc			

RFP 2018 - 009 Attachment 1 - LABORATORY

		Anticipated			
Test Name	CPI	volume	lurn around Time (indicate hours/days)	Price	Performing Lab
C-PEPTIDE	84681	88			
CRAB (F23) IGE	86003	14			
CRE CULTURE	87081	280			
C-REACTIVE PROTEIN	86140	-			
CREATININE, PERITONEAL FLU	82570	7			
CRYOGLOBULIN QL ANALYSIS	82595	19			
CRYPTOCOCCUS AB TITER	86403	1			
CRYPTOCOCCUS AG TITER,LA,	86403, 87999	5			
CRYPTOCOCCUS AG, LA, CSF	86403, 87899	3			
CRYPTOSPORIDIUM AG,STOOL	87272	13			
CUCUMBER (F244) IGE	86003	1			
CUL, FUNGUS, SKIN, HAIR, NAIL	87101	9			
CULT, FUNGUS, SKIN, HAIR, NAI	87101	6			
CULTURE, FUNGUS, BLOOD	87103	2			
CULTURE, FUNGUS, MISC	87101, 87102	35			
CULTURE, FUNGUS, RESPIRATOR	87102	21			
CULTURE, URINE	87086, 87087	3			
CULTURE, WOUND, SUPERFICIAL	87070	1			
CMV AB (IGG,IGM)	PROFILE	96			
AMNIOTIC FLD PANEL	PROFILE	18			
CYCLIC CITRULLINE PEP IGG	86200	338			
CYCLOSPORINE, LCMSMS, BLOOD	80158	14			
CYSTICERCUS AB, ELISA, CSF	86682	2			
CYSTICERCUS IGG AB, WB(SER	86682	9			
D. FARINAE (D2) IGE	86003	88			
D. PTERONYSSINUS (D1) IGE	86003	89			
DANDELION (W8) IGE	86003	2			
DENGUE AB (IGG,IGM),AG PN	PROFILE	1			
DENGUE FEVER AB (IGG,IGM)	PROFILE	၉			
DENGUE VIRUS NS1 ANTIGEN	87449	-			
DESMOGLEIN ABS (1 AND 3)	83520	-			
DEXAMETHASONE	80299	-			
DHEA SULFATE	82627	178			
DHEA,SERUM EXTRACTION, RI	82626	38			
DIAZEPAM & NORDIAZEPAM,SE	80154, 80346	2			
DIFF.ALONE****POLY	85007	1			
DIGITOXIN,SERUM/PLASMA	80299	1			
DIHYDROTESTOSTERONE, LC/MS	80327	5			
DIPHTHERIA ANTITOXOID AB	86648	1			
DNA AB (DS) CRITHIDIA	86255	46			
DNA ANTIBODIES, NATIVE	86225	_			
DNA(DS) AB CRITHIDIA TITE	86256	10			

RFP 2018 - 009 Attachment 1 - LABORATORY

CPT   Volume Turn anound Turne (indicate hours/disps)   Price     802/35   45   Price   Price     802/34   45   Price   Price   Price     802/34   1   Price   Price			Anticipated Annual			
86215 86003 80346 8037 80307 80100, PROFILE 85613 86003 86003 86682 86682 86682 86682 86682 86682 86682 86682 86683 86625, PROFILE 82668 85652 86003 86255, PROFILE 82668 85652 82673 82673 82673 82673 82673 82673 82673 82673 82673 82673 82693 81241, PROFILE 82260 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220	Test Name	CPT	Volume	Turn around Time (indicate hours/days)	Price	Performing Lab
86003 80346 80346 80307 80100, PROFILE 86003 86003 86604, 86666 88753 86608, 86666 87739 86682 86603 86625, PROFILE 86003 86255, PROFILE 82668 85652 82677 82677 82677 82677 82677 82677 82678 81241, PROFILE 82693 81168 82593 81168 82593 81169 82593 81169 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220	DNASE-B AB	86215	8			
80346 80307 80100, PROFILE 85613 86003 86003 86604, 86666 86753 86682 86682 86682 86682 86683 86682 86603 86003 86255, PROFILE 86003 86255, PROFILE 82668 85652 82677 82677 82677 82677 82677 82670 82693 80169 82693 80169 82593 81241, PROFILE 82593 81241 82520 85220 85220 85220 85220 85220 85220 85220 85220 85220	DOG DANDER (E5) IGE	86003	45			
80307 80100, PROFILE 85613 86003 86003 86003 86682 86682 86682 86682 86682 866835 86003 86255, PROFILE 82668 85652 82677 82677 82677 82677 82679 82693 80169 82593 80169 82593 81241, PROFILE 82500 85220 85220 85220 85230 85230 85230 85230 85230 85230 85230 85230 85230 85230 85230 85230	DRG TOX BENZO, QN, U	80346	1			
80100, PROFILE   85613   86003   86003   86504   86666   8753   86682   86822   86003   86625   86003   86255   86003   86255   86003   86255   86003   86255   82672   82672   82672   82673   82650   8225	DRUG SCREEN PANEL 9, MEC	80307	1			
S (E86) IGE         86003           S (E86) IGE         86003           AB (IGG,MI)         86609, 86666           IGG         86753           PROFILE         87799           S AB (IGG, WB         86682           IGG         86682           S AB (IGG) WB         86682           I GE         86003           AB         86682           I IGE         86003           I I IGE         86003           I I IGE         86003           I I I I I I I I I I I I I I I I I I I	DRUG TEST, GENERAL TOX, S/P	80100, PROFILE	2			
86003 86003 86003 86003 86753 PROFILE 87799 86682 86682 86682 86682 86682 86682 86603 86255 86003 86255 80003 86255 82672 82672 82672 82672 82672 82672 82672 82672 82672 82672 82673 82672 82673 82673 82673 82673 82673 82673 82673 82673 82673 82620 85250 85250 85250 85250 85250 85250 85250 85250 85260 85270 85270 85270 85280	DRVVT 1:1 MIX	85613	22			
86003 86609, 86666 86753 86753 PROFILE 87799 86682 86682 86682 86682 86003 86255, PROFILE 82668 8255, PROFILE 82672 82672 82672 82672 82672 82672 82672 82672 82672 82672 82672 82672 82672 82672 82673 82672 82673 82673 82673 82673 82673 82670 85250 85250 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220	DUCK FEATHERS (E86) IGE	86003	3			
## 86609, 86666  ## 86753  ## 86753  ## 8682  ## 8683  ## 8683  ## 8683  ## 8683  ## 8683  ## 8683  ## 8683  ## 8683  ## 8683  ## 8683  ## 8683  ## 8683  ## 86830  ## 86830  ## 86830  ## 86830  ## 86830  ## 86830  ## 86830  ## 86830  ## 86830  ## 86830  ## 86830  ## 86830  ## 86830	E. PURPURASCENS(M14) IGE	86003	1			
86753  PROFILE 87799 86682 86682 86682 86003 86003 86255, PROFILE 82668 82652 82672 82672 82672 82673 82672 82679 82670 82670 82670 82670 82670 82670 82670 82670 82670 82670 82620 82620 82620 85220	E.CHAFFEENSIS AB (IGG,M)	86609, 86666	1			
PROFILE   87799   86682   86682   86682   86003   86003   82672   82672   82672   82672   82672   82679   82670   82620   82520   85220   85	E.HISTOLYTICA IGG	86753	3			
86682 86682 86682 86603 86003 86255 86003 86255 86268 82672 82672 82672 82672 82672 82672 82672 82672 82672 82672 82672 82672 82672 82672 82672 82672 82672 82672 82672 82673 82672 82673 82673 82673 82620 85220	EBV ANTIBODY PROFILE	PROFILE	126			
86682 86682 86003 86003 86003 86235 86235 86255, PROFILE 82668 82652 82672 82672 82672 82672 82672 82673 82672 82673 8168 8168 8168 8168 8169 811241, PROFILE 82520 85220	EBV DNA,QN,PCR	87799	2			
86682         86682           86003         PROF           86003         PROF           86003         86255           N9) IGE         86255         PROFILE           X         86255         PROFILE           X         86255         PROFILE           X         86255         PROFILE           RUM         82677         82673           IM         80168         82673           IM         80168         82670           AL         85260         AL           AL         85250         AL           AL         85230         AL           AL         85240         AL           AL         85260         AL           AL         85260         AL           AL         85280         AL           AL         85280         AL           AL         85280         AL           AL	ECHINOCOCCUS AB (IGG) WB	86682	1			
REOD3           PROF           86003           PROF           86255           Av9) IGE         86255           REUM         86255           REUM         82677           REUM         82673           IM         80168           BODY,DA         80169           DDY,DA         80169           IM         80169           IM         80169           IM         80260           AL         85250           AL         85250           INTATION         81241           PROFILE         INAL           85230         INAL           AL         85260           AL         85260           AL         85260           AL         85280           AL         85280      <	ECHINOOCCUS AB	86682	8			
PROF   PROF   86003   86255   86255   86255   86255   86255   86255   86255   86255   86255   86255   86255   86255   82668   82652   82677   82677   82677   82679   82670	EGG MIX (F245) IGE	86003	19			
RNP)         86003           RNP)         86235           ANTIBODY SCREE         86255           BNTAIN (W9) IGE         86255           RETIN         82668           JM         82652           JM         82677           RACT, SERUM         82672           JM         82672           JM         82672           JM         82673           JCOTAL, SERUM         82673           JCOTAL, SERUM         82679           SANTIBODY, DA         82679           SANTIBODY, DA         82690           SANTIBODY, DA         8520           INCTIONAL         82250           SIDEN) MUTATION         81241           RIDEN) MUTATION         81241           RIDEN) MUTATION         85220           INCTIONAL	ELECTROLYTES, FECES	PROF	141			
86235 86255 86003 86255, PROFILE 82668 85652 82677 82677 82671 82672 82679 80168 82683 80169 80169 81241, PROFILE 81241 85220 85220 85240 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220	ELM (T8) 1GE	86003	14			
86255, PROFILE 86003 8255, PROFILE 82668 85652 82677 82677 82673 82679 82679 82679 82679 82679 82679 82670 82670 85210 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220 85220	ENA AB (SM/RNP)	86235	1			
86003 86255, PROFILE 82668 85652 82677 82671 82672 82672 82672 82679 80168 80169 80169 80169 81241, PROFILE N 85220 85230 85240 85240 85240 85240 85240 85250 85250 85250 85250 85250 85250 85250 85250 85250 85250 85250 8520	ENDOMYSIAL ANTIBODY SCREE	86255	9			
86255, PROFILE           82668           82668           85652           82677           82671           82672           A           82679           A           82679           A           82679           A           82679           A           82693           B           82600           AI           85250           AI           85220           AI           85220           AI           85230           AI           85200           AI <tr< td=""><td>ENGLISH PLANTAIN (W9) IGE</td><td>86003</td><td>7</td><td></td><td></td><td></td></tr<>	ENGLISH PLANTAIN (W9) IGE	86003	7			
82668   82668   85652   85652   82677   82677   82677   82677   82677   82672   82672   82672   82679   82679   82679   82679   82693   92690   9269	EPIDERMAL AB W/RFX	86255, PROFILE	-			
85652   82677   82677   82677   82677   82677   82677   82671   82672   82672   82672   82672   82679   82679   82679   82679   82693   92690   9269	ERYTHROPOIETIN	82668	26			
82677 82671 82672 82679 82679 80168 80169 80169 85260 85250 85220 85220 85220 85220 85220 85220 85230 85240 85260 85260 85260	ESR, WESTERGREN	85652	-			
82671 82672 82679 80168 80169 80169 A 86000 85210 85250 10 81241 85220 85240 85240 85260 85280 85280	ESTRIOL, SERUM	82677	က			
82672 82679 80168 80169 80169 A 86000 85210 85250 10 81241 85220 85220 85240 85260 85260 85280 85280	ESTROGENS, FRACT, SERUM	82671	21			
82679   80168   80168   80168   82693   80169   8210   85210   85250   81241   85220   85220   85260   85260   85260   85260   85280	ESTROGENS, TOTAL, SERUM	82672	40			
80168   82693   82693   80169   80169   85210   85250   81241   85220   85220   85220   8526	ESTRONE, SERUM	82679	80			
82693   80169   80169   80169   86000   85210   81241   81241   85220   85260   85260   85260   8528	ETHOSUXIMIDE,SERUM	80168	1			
(,DA 86000 85000 85210 85250 ATIO 81241 ATION 81241 85220 1 85240 1 85260 85270 85280 85280	ETHYLENE GLYCOL	82693	6			
ATIO 85210  85210  85250  ATIO 81241  ATION 85220  85240  1 85260  85270  85280  85280	EVEROLIMUS, BLOOD	80169	2			
#5210 #5250 #TIO #1241 #TION #1241 #5220 #5220 #5230 #5240 #5260 #5260 #5260 #5260 #5260 #5260 #5260 #5260	F.TULARENSIS ANTIBODY,DA	86000	-			
ATIO 81241, PROFILE  ATION 81241  85220  85230  L 85240  85260  85260  85260  85260  85270  85280	FACTOR II, FUNCTIONAL	85210	2			
81241, PROFILE 81241 85220 85230 85240 85260 85260 85280 85280	FACTOR IX, FUNCTIONAL	85250	က			
81241 85220 85230 85240 85260 85270 85280	FACTOR V (LEIDEN) MUTATIO	81241, PROFILE	84			
85220 85230 85240 85260 85270 85280	FACTOR V (LEIDEN)MUTATION	81241	33			
85230 85240 85260 85270 85280 F	FACTOR V, FUNCTIONAL	85220	7			
85240 85260 85270 85280 85603	FACTOR VII, FUNCTIONAL	85230	1			
85260 85270 85280 86003	FACTOR VIII, FUNCTIONAL	85240	23			
85270 85280 86003	FACTOR X, FUNCTIONAL	85260	4			
85280	FACTOR XI, FUNCTIONAL	85270	1			
86003	FACTOR XII, FUNCTIONAL	85280	-			
COOCO	FALSE RAGWEED (W4) IGE	86003	25			

RFP 2018 - 009 Attachment 1 - LABORATORY

		Anticipated Annual		ć	Dorforming
Test Name	CPI	volume	Lurn around Time (Indicate nours/days)	a Ce	Telolining Lab
FECAL FAT, QL	82705, 87205	σ			
FECAL LIPIDS, TOTAL	82710	2			
FELBAMATE, SERUM	80299	1			
FENTANYL AND NORFENTANYL	80354	-			
FERRET EPITH (E217) IGE	86003	1			
FETAL ERYTHROCYTES	85460	31			
FISH, LOCUS SPECIFIC X1	PROFILE	-			
FISH, LOCUS SPECIFIC X2	PROFILE	-			
FISH, LOCUS SPECIFIC X3	PROFILE	2			
FISH, PDGFRB, 5Q33.1	PROFILE	-			
FISH, AML M3, PML/RARA	PROFILE	2			
FISH, B-CELL CLL PANEL	PROFILE	4			
FISH, BURKITT'S/NHL/ALL	PROFILE	-			
FISH.CML/ALL.BCR/ABL	PROFILE	9			
FISH, MANTLE CELL LYMPHOMA	PROFILE	<b>-</b>			
FISH, MDS PANEL 5.7,8,20	PROFILE	11			
FISH.MM.IGH/FGFR3.t(4:14)	PROFILE	1			
FISH, MM, IGH/MAF, t(14:16)	PROFILE	-			
FISH, MYELOMA, 17p-, rea14q	PROFILE	12			
FISH, MYELOMA, IGH PANEL	PROFILE	-			
FISH, PRADER WILLI	PROFILE	9			
FLOUNDER (SAS) IGE	86003	က			
FLUPHENAZINE, SERUM/PLASMA	80342	3			
FOLATE, RBC	82747	2			
FOLATE, RBC & HCT	82747	3			
FREE KAPPA & LAMBDA W/ RA	83883	163			
FRUCTOSAMINE	82985	734			
FTA-ABS,SERUM	86780, 86781	332			
FUNGITELL 1-3 B-D GLUCAN	87449	9			
FUNGUS, DIR KOH; HAIR, SKIN,	87220	14			
FUNGUS, DIR KOH; NOT HAIR, S	87206	11			
FUSARIUM MONILIFORME (M9)	86003	1			
G-6-PD,QN	82955	12			
GABAPENTIN	80171, 80299	1			
GAD-65 AB	86341	19			
GALACTOSE 1-PHOSPHATE URI	82775	1			
GALACTOSE-ALPHA-1,3 IGE	86003	2			
GANGLIOSIDE AB PANEL 6	PROFILE	1			
GARLIC (F47) IGE	86003	3			
GASTRIN, SERUM	82941	14			
GBM AB IGG	83520	13			
	0000	1			

RFP 2018 - 009 Attachment 1 - LABORATORY

Test Name         CPT           GIARDIA AG, EIA, STOOL         87328, 87329           GLIADIN AB (IGG,A)         82943           GLUCAGON         82943           GLUCAGON         82943           GLUCAGON         82943           GLUCAGON         82943           GLUCAGON         82003           GLUCAGON         84378           GALYCOMARK         84378           GOOSE FATHERS (E70) IGE         86003           GOOSE FATHERS (E70) IGE         86003           GRAPE (F259) IGE         86003           GRAPE (E259) IGE         86003           GROWTH HORMONE         7 SPEC           GROWTH HORMONE         7 SPEC           GROWTH HORMONE, 5 SPEC         83003           H. BRAZILIENSIS/LATEX(K82         86003           H. HALODES (M8) IGE         86003		Tum around Time (indicate hours/days)	Price	Performing Lab
IGE SPEC SPEC (K82				
F70) IGE IGE IGE E, 7 SPEC E, 5 SPEC TEX(K82)	10 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7			
(E70) IGE () IGE S) IGE NE, 7 SPEC NE, 5 SPEC ATEX(K82	6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			
(E70) IGE 5) IGE NE, 7 SPEC NE, 5 SPEC ATEX(K82	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			
HERS (E70) IGE  3) I GE (F209) IGE (F209) IGE RMONE RMONE, 7 SPEC RMONE, 5 PEC RMONE, 5 PEC RMONE, 6 PEC RMONE, 7 SPEC	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			
	2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			
	2 2 2 1 1 1 1 1 2 8 2 8 3 3 3			
	2 2 1 1 1 1 2 2 2 2 2 2 8 1 1 1 1 1 1 1			
	2 1 1 15 15 2 2 2 2 2 8 1 1 1 1 1 1 1 1 1 1 1 1 1 1			
	1 15 15 1 1 1 1 1 1 1 3 3			
	1 15 1 2 2 8 2 8 1 1 1 1 1 3 3 3			
	15 2 28 28 1 1 1 1 3			
	2 28 28 1 1 1 506 3			
	2 28 1 1 1 506 3			
	28 1 1 506 3			
	1 1 506			
	506			
H. HALODES (M8) IGE	506			
H.PYLORI AG,QL,STOOL	8			
HAZELNUT (F17) IGE 86003				
HB E AB 86707	67			
HB E AG 87350	143			
HBV DNA, QN PCR 87517	_			
HCV GENOTYPE, LIPA	167			
HCV RNA NS5A DRUG RESISTA 87902	26			
3 DRUG RESISTA	ည			
	712			
HEAVY METALS, BLOOD PROFILE	12			
HEAVY METALS1, URINE PROFILE	111			
HEMOGLOBIN A1C 83036				
HEMOGLOBINOPATHY EVAL PROFILE	20			
HEMOGRAM & PLATELET COUNT 85027	-			
HEPARIN ANTI-Xa ASSAY 85520	2			
HEPATIC FUNCTION PANEL 80076	2			
HEPATITIS B VIRAL PCR 87517	194			
HEPATITIS D AB, TOTAL 86692	3			
HEPATITIS D IGM AB EIA 86692	20			
HEREDITARY HEMOCHROM DNA 81256	7			
HERPES TYPE 1 & 2, DNA, PCR	87529 92			
HEV AB (IGG) 86790	2			
HEV AB (IGM) 86790	2			
HISTAMINE RELEASE 86343	1			
HISTONE AB 83516	14			

RFP 2018 - 009 Attachment 1 - LABORATORY

	Fa	Anticipated Annual Volume	Time storing Time (indicate hours/davs)	Price	Performing Lab
iest Name	- 50				
HISTOPLASMIA AB,ID	08000	D.			
HLA CLAS I A,B,C DNA TYPI	813/2				
HLA-B27	86812	33			
HLA-B57 TYPING	81381	41			
HOMOCYSTEINE	82131, 83090	212			
HONEY (F247) IGE	86003	,			
HONEY BEE (11) IGE	86003	-			
HOUSE CALL		r.			
HOUSE DUST-HS (H2) IGE	86003	т			
HSV TYPE 1 & 2 IGG ANTIBO	PROFILE	362			
HU AB,IFA W/RFX WB	86255	က			
HUMAN ANTI-MOUSE AB, ELISA	83520	ю			
HYPERSENS PNEUMONITIS SCR	PROFILE	2			
HYPOGLYCEMIC PANEL SERUM/	83789	15			
ID BY PROBE	87149	54			
IgD.SERUM	82784	4			
IGE.SERUM		72			
IGF BINDING PROTEIN-1	83519	-			
IGF BINDING PROTEIN-3	83519	53			
IGF-1 ELECTROCHEMILUMINES	84305	144			
IGF-2, LC/MS	82542	10			
IGG SUBCLASS 4	82787	2			
IGG SUBCLASSES	PROFILE	22			
IGG SYNTHESIS RATE	PROFILE	ဂ			
IGG, CSF	82784	59			
IMIPRAMINE & DESIPRAMINE,	80335	1			
IMMUNOFIXATION, SERUM	86334	37			
IMMUNOFIXATION, URINE	86335	1			
INFLUENZA AB, TYPE A & B	86710	14			
INFLUENZA TYPE A AB	86710	1			
INFLUENZA TYPE B AB	86710	1			
INHIBIN A	86336	99			
INSULIN AB, RIA	86337	12			
INSULINISERUM	83525	290			
INTERLEUKIN 6	83520	1			
INTRINSIC FACTOR BLOCKING	86340	44			
IODINE, RANDOM URINE	82542	3			
IODINE, SERUM/PLASMA	82542	2			
ISLET CELL AB, IFA	PROFILE	11			
ISLET CELL AG 512 ANTIBOD	83519, 86341	1			
JAK2 EXONS 12 AND 13 MUT	81403	1			
JAK2 V617F MUTATION	81270	30			

RFP 2018 - 009 Attachment 1 - LABORATORY

	_	- Iciday			
Test Name	CPT	Volume	Turn around Time (indicate hours/days)	Price	Performing Lab
JC VIRUS DNA QUANT PCR	87799	2			
JC VIRUS DNA,QN,CSF	87799	1			
JO-1 AB	86235	50			
JOHNSON GRASS (G10) IGE	86003	4			
JUNE GRASS (G8) IGE	86003	96			
KIWI FRUIT (F84) IGE	86003	5			
LACOSAMIDE, SERUM/PLASMA	80299	1			
LACTOFERIN, QNT, STOOL	83631	4			
LACTOFERRIN, QL, STOOL	83630	2			
LAMB (F88) IGE	86003	1			
LAMBS QUARTERS (W10) IGE	86003	4			
LAMOTRIGINE	80175	70			
LEAD,BLOOD	83655	2153			
LEGIONELLA AG, EIA, URINE	87449	293			
LEGIONELLA CULTURE	PROFILE	22			
LEGIONELLA PNEUMOPHLIA AB	86713	3			
LEMON (F208) IGE	86003	2			
LEPTIN	82397	c)			
LEPTOSPIRA AB,IHA	86720	-			
LEPTOSPIRA DNA,QL,RT-PCR	87798	4			
LETTUCE (F215) IGE	86003	-			
LEUKOCYTES,STOOL	89055	49			
LEVETIRACETAM	80177	591			
LIDOCAINE	80176	_			
LIPASE PERITONEAL	83690	-			
LIPASE, JP DRAINAGE	83690	1			
LIPASE, PLEURAL FLUID	83690	-			
LIPID PANEL	80061	80			
LIPOPROTEIN (A)	83695	4			
LISTERIA AB	86609	1			
LIVER, FIBROTEST-ACTITEST	0001M	100			
LKM-1 ANTIBODY IGG	86376	28			
LOBSTER (F80) IGE	86003	15			
LORAZEPAM	80346	2			
LUPUS ANTICOAG EVAL W/RFL	PROFILE	291			
LUPUS ANTICOAG, HEXAGONAL	85598	114			
LYME DISEASE(B.SPP)DNA,SF	87801	15			
LYMPHOCYTE SUBSET PANEL 1		3			
LYMPHOCYTE SUBSET PANEL 1	PROFILE	-			
LYMPHOCYTE SUBSET PANEL 1	PROFILE	7-			
LYMPHOCYTE SUBSET PANEL 3	PROFILE	176			
LYSOZYME.SERUM	85549	26			

RFP 2018 - 009 Attachment 1 - LABORATORY

		Anticipated Annual			
Test Name	CPT	Volume	Turn around Time (indicate hours/days)	Price	Performing Lab
M.HOMINIS/UREAPLASMA CULT	87109	_			
M.PNEUMONIAE AB (IGG), EIA	86738	29			
M.PNEUMONIAE AB (IGM)	86738	39			
MAGNESIUM, RANDOM URINE	83735	8			
MAGNESIUM, RBC	83735	15			
MANGANESE, WHOLE BLOOD	83785	1			
MANGO FRUIT (F91) IGE	86003	2			
MAPLE (BOX ELDER) (T1) IG	86003	89			
MARIJUANA, CONFIRMATION	80349	1			
MATERNAL SERUM SCREEN 4	PROFILE	410			
MDMA SERUM/PLASMA	80359	1			
MELONS (F87) IGE	86003	2			
MERCURY, BLOOD	83825	4			
METANEPHRINES, 24HR URINE	83835	33			
METANEPHRINES, FRACTIONATE	83835	46			
METANEPHRINES, RANDOM URIN	PROFILE	1			
METHADONE	80358, 83840	1			
METHEMOGLOBIN REDUCT	82657	1			
METHYLMALONIC ACID, SERUM	83921	40			
MICROALBUMIN, RAND U(W/CR)	PROFILE	1			
MICROSCOPIC EXAM, URINE	81015	1			
MILK (F2) IGE	86003	13			
MILK COMPONENT PANEL	PROFILE	1			
MISCELLANEOUS TEST	MISC	48			
MITOCHONDRIA M2 AB IGG	83520	-			
MITOCHONDRIAL AB W/RFX	86255	72			
MOLD ID	87107	22			
MOLECULAR BIOLOGY	PROFILE	31			
MOUSE EPITHELIA (E71) IGE	86003	2			
MPL W515 AND MPL S505 MUT	81402	လ			
MTHFR, DNA M	81291	1			
MUCOR RACEMOSUS (M4) IGE	86003	1			
MUGWORT (W6) IGE	86003	58			
MUMPS AB (IGG)	86735	55			
MUMPS AB (IGM), IFA	86735	17			
MUMPS VIRUS RNA, RT PCR	87798	1			
MUSHROOM (F212) IGE	86003	1			
MUSK QN TITER AB TEST	83519	9			
MUSTARD (F89) IGE	86003	-			
MVISTA HISTOPLASM QN,AG	87385	29			
MYCOBAC CULTURE & STAIN,S	PROFILE	453			
	07447	ď			

RFP 2018 - 009 Attachment 1 - LABORATORY

SE STE STAIN  STAIN  TUM  TUM  TUM  TUM  TUM  SE STE  STAIN  STAI			Anticipated Annual			
PROFILE  PROFILE  PROFILE  PROFILE  PROFILE  87556  87556  80180  80180  80180  80180  80180  80329  86021  80329  86032  86033  86003	Test Name	CPT	Volume	Turn around Time (indicate hours/days)	Price	Performing Lab
PROFILE PROFILE PROFILE PROFILE PROFILE PROFILE 87556 87556 87156 80180 886021 886021 886021 886023 886256 80182,80335 86003	MYCOBACTERIA CULT & STAIN	PROFILE	9			
PROFILE PROFILE PROFILE PROF 8756 8756 8756 80180 80180 886021 886021 886021 886021 88603 886256 80182,80335 86003	MYCOBACTERIA CULT&STAIN,B	PROFILE	5			
PROFILE PROF 8756 8756 80180 S0180 S0180 S8373 S8021 S8021 S8023 S8033 S8033 S8250, 86316 S8023 S8255 S0182, 86316 S8023 S8255 S0182, 86316 S8003	MYCOBACTERIA CULT, BODY FL	PROFILE	55			
PROF 87556 87556 80180 80180 80180 80180 80180 86021 83874 83874 86032 86033 83520, 86316 86021 86033 83520, 86316 86033 86003	MYCOBACTERIA CULT, BRONCHI	PROFILE	120			
87556 87566 80180 80180 80180 80180 80521 80621 80329 86037 86003	MYCOBACTERIA CULT,CSF	PROF	10			
87556 80180 80180 80180 83873 86021 83874 83874 83874 80329 86032 86033 83520, 86316 86021 80323 80526 80182, 80335 80182, 80335 80182, 80335 80033 86003 87169	MYCOBACTERIA, PCR, SPUTUM	87556	22			
NUIAE,PCR     80180       81873     86021       86021     83874       83874     83874       80329     86357       8603     8603       ASE     86021       MISMS     86021       86021     86021       MISMS     83520, 86316       86021     86021       MISMS     83516       86021     86023       85749     86003       86003     86003       86003     86003       86003     86003       86003     86003       86003     86003       84999     PROFILE       N/NY     PROFILE       RVCR)     84999       PPROFILE     PROFILE       UR     80365       GCMS,UR     80365       UR     8003       ON     87169       NA     87169	MYCOBACTERIA, PCR, SPUTUM	87556	1			
ST581   ST582   ST58	MYCOPHENOLIC ACID	80180	4			
83873 86021 83874 83874 83874 83874 80329 86357 86033 86021 WSMS 83520, 86316 86021 83520, 86316 86021 83516 86023 86003 87488 83918, 83921 84999 84999 84999 8761LE 87688 87656 87689	MYCOPLASMA PNEUMONIAE, PCR	87581	2			
86021   83874   83874   83874   83874   83874   80329   86357   86003   86021   86021   86021   86021   86003   8600	MYELIN BASIC PROTEIN	83873	9			
83874 83874 83874 80329 86357 86003 86021 86021 80323 83520, 86316 86021 80323 83516 86023 87449 N PROFILE 86003 86003 86003 86003 86003 ROOSI 86003 ROOFILE 83918, 83921 ROOFILE 83918, 83921 ROOFILE 83918, 83921 84999 PROFILE 83918, 83921	MYELOPEROXIDASE AB	86021	2			
83874  PROFILE 80329 86357 86003 83520, 86316 86021 80323 83516 86255 80182, 80335 87449 N PROFILE 86003 86003 86003 86003 86003 86003 ROOSI 86003 ROOSI 86003 ROOSI 86003 87469 87499 RROFILE 83918, 83921 84999 RROFILE 83918, 83921	MYOGLOBIN URINE	83874	13			
PROFILE  80329  86357  86003  83520, 86316  86021  80323  83516  86255  80182, 80335  87449  N PROFILE  86003  86003  86003  86003  86003  ROOSI  86003  ROOSI  86003  ROOSI  86003  ROOSI  86003  86003  86003  86003  86003  86003  86003  86003  86003  86003  86003  86003  86003  86003  86003  87169  87169	MYOGLOBIN, SERUM	83874	2			
86357 86033 83520, 86316 86021 80323 83526, 86316 86021 80426 86255 80182, 80335 87449 86003 87469 876FILE 83918, 83921 84999 PROFILE 83918, 83921	MYOSITIS PLUS JO-1	PROFILE	9			
86357 86003 88021 80323 83520, 86316 80221 80323 83516 86255 80182, 80335 87449 86003 87169 87169	NAPROXEN	80329	1			
86003 83520, 86316 86021 80323 83516 86255 80182, 80335 87449 N PROFILE 86003 87169 87061LE 83918, 83921 84999 PROFILE 83918, 83921 84999 87061LE 83918, 83921 84999 87061LE 83918, 83921 84999 87061LE 83918, 83921 84999 87061LE 87065 87063 87065 87063 87063 87063 87063 87063 87063 87063 87063 87063	NATURAL KILLER CELLS	86357	1			
83520, 86316 86021 80323 83516 86255 80182, 80335 87449 N PROFILE 86003 86003 86003 86003 86003 86003 ROFILE 83918, 83921 RAPELE 83918, 83921 RROFILE 83918, 83921 RROFILE 83918, 83921 84999 RROFILE 83918, 83921	NETTLE (W20) IGE	86003	1			
86021 80323 83516 86255 80182, 80335 87449 N PROFILE 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 87051LE 83918, 83921 84999 PROFILE 83918, 83921 84999 87051LE 83965 86003 87169	NEURON SPECIFIC ENOLASE	83520, 86316	98			
80323 83516 86255 80182, 80335 87449 N PROFILE 86003 86003 86003 86003 86003 86003 86003 86003 PROFILE 83918, 83921 84999 PROFILE 83918, 83921	NEUTROPHIL AB, FC	86021	1			
83516 86255 80182, 80335 80182, 80335 87449 IN PROFILE 86003 86003 86003 86003 86003 86003 86003 86003 86003 86003 874999 PROFILE 83918, 83921 84999 PROFILE 80365 80365 80365 80365 80365 80365 80365 86003 87169	NICOTINE/COTININE, LCMSMS	80323	2			
86255 80182, 80335 87449 IN PROFILE 86003 86003 86003 86003 86003 86003 86003 86003 86003 PROFILE 83918, 83921 PROFILE 83918, 83921 PROFILE 80365 80365 80365 80365 80365 80365 80365	NMO,IGG AB,ELISA	83516	3			
80182, 80335 8749 IN PROFILE 86003 86003 86003 86003 86003 86003 86003 86003 PROFILE 83918, 83921 84999 PROFILE 80365 PROFILE 80365 80365 80365 80365 86003 87169	NMO/AQP4-IGG CBA,CSF	86255	1			
87449 IN PROFILE 86003 86003 86003 86003 86003 86003 86003 87499 PROFILE 83918, 83921 84999 PROFILE 87499 PROFILE 80365 80365 80365 86003 87169	NORTRIPTYLINE, SERUM	80182, 80335	2			
N   PROFILE	NORWALK-LIKE VIRUS AG STL	87449	1			
86003 86003 86003 86003 86003 86003 86003 PROFILE 83918, 83921 84999 PROFILE PROFILE 80365 80365 86003 87169	O & P,CONCENTRATION&STAIN	PROFILE	436			
86003 83916 86003 86003 86003 86003 86003 PROFILE 83918, 83921 84999 PROFILE PROFILE 80365 80365 86003 87169 82555	OAK WHITE IGE	86003	98			
83916 86003 86003 86003 86003 PROFILE 83918, 83921 84999 PROFILE PROFILE 80365 80365 86003 87169 82555	OAT (F7) IGE	86003	4			
86003 86003 86003 86003 PROFILE 83918, 83921 84999 PROFILE PROFILE 80365 80365 82656 86003 87169 82555	OLIGOCLONAL BANDS, CSF	83916	19			
86003 86003 PROFILE 83918, 83921 84999 PROFILE PROFILE 80365 80365 82656 86003 87169	ONION (F48) IGE	86003	1			
86003 PROFILE 83918, 83921 84999 PROFILE PROFILE 80365 5,UR 82656 86003 87169 87255	ORANGE (F33) IGE	86003	ო			
PROFILE 83918, 83921 84999 PROFILE PROFILE 80365 8,UR 80365 86003 87169 86255	OREGANO (F283) IGE	86003	<b>←</b>			
83918, 83921 84999 PROFILE PROFILE 80365 5,UR 82656 86003 87169 86255	ORGANIC ACIDS, FULL, QN, NY	PROFILE	4			
84999 PROFILE PROFILE 80365 5,UR 80365 82656 86003 87169 86255	OROTATE, URINE	83918, 83921	_			
PROFILE  PROFILE  80365 5,UR  80365 82656 86003 87169 87255	OSMOLALITY, STOOL	84999	6			
PROFILE 80365 5,UR 80365 82656 86003 87169 86255	OVA AND PARASITE, 2 SPECI	PROFILE	2			
MS,UR 80365 82656 86003 87169 86255	OXALIC ACID,24HR UR(W/CR)	PROFILE	1			
MS,UR 80365 82656 86003 87169 86255	OXYCODONE & METAB UR	80365	1			
82656 86003 87169 86255	OXYCODONE CONFIRM, GCMS, UR	80365	1			
86003 87169 86255	PANCREATIC ELASTASE 1	82656	8			
87169	PAPER WASP (14) IGE	86003	1			
86255	PARASITE IDENTIFICATION	87169	2			
	PARIETAL CELL AB W/RFX	86255	80			

RFP 2018 - 009 Attachment 1 - LABORATORY

		Anticipated Annual			
Test Name	CPT	Volume	Turn around Time (indicate hours/days)	Price	Performing Lab
PARVOVIRUS B19 AB (IGG)	86747	71			
PARVOVIRUS B19 AB (IGG,M)	86747	40			
PARVOVIRUS B19 AB (IGM)	86747	9			
PARVOVIRUS B19 DNA QN PCR	87799	3			
PCB PANEL, CONGENERS, S/P	82441	105			
PEA (F12) IGE	86003	1			
PEACH (F95) IGE	86003	3			
PEANUT (F13) IGE	86003	30			
PEANUT COMPONENT PANEL	86008	5			
PEAR (F94) IGE	86003	2			
PECAN NUT (F201) IGE	86003	-			
PECAN TREE IGE	86003	1			
PENICILLIUM NOTATUM (M1)	86003	50			
PHENOTYPE, RBC AG	86905	-			
PHENYLALANINE, NY	84030	4			
PHENYTOIN, FREE	80186	σ			
PHOSPHATE, RANDOM URINE W/	PROFILE	2			
PHOSPHATIDYLSERINE(G,A,M)	86148	2			
PHOSPHOLIPID NEUTR	85597	56			
PICK UP STAT	99199	-			
PINEAPPLE (F210) IGE	86003	ß			
PINWORM EXAMINATION	87172, 87208	5			
PISTACHIO (F203) IGE	86003	1			
PLASMA RENIN ACTIVITY	84244	55			
PLASMINOGEN, ANTIGENIC	85421	2			
PLASMINOGEN, FUNCTIONAL	85420	1			
PLATELET AB (IGG), DIRECT	86023	4			
PLATELT AB SCR(INDIRECT)	86022	ю			
PNEUMOCYSTIS CARINII DFA	PROFILE	43			
PNH W/FLAER (HIGH SENSI)	PROFILE	-			
PNH W/FLAER(HIGH SENSIT)	PROFILE	-			
POLIOVIRUS(1,3)AB,NEUTRAL	86382	9			
PORK (F26) IGE	86003	00			
PORPHYRINS, TOTAL, PLAS.	82542	2			
POSTNATAL, OLIGO-SNP ARRAY	81229	14			
POTATO (F35) IGE	86003	1			
PRIMIDONE & PHENOBARBITAL	PROFILE	5			
PROINSULIN	84206	16			
PROLACTIN, DILUTION STUDY	84146	8			
PROTEIN C, ANTIGENIC	85302	40			
PROTEIN C, FUNCTIONAL	85303	112			
	ייסיים	•			

RFP 2018 - 009 Attachment 1 - LABORATORY

Test Name PROTEIN ELECTRO,W/TP,UR PROTEIN ELECTRO,W/TPROT,S PROTEIN ELECTRO,W/TPROT,S PROTEIN S,ANTIGENIC PROTEIN S,FUNCTIONAL PROTEINASE-3 AB	Tab				
PROTEIN ELECTRO,W/TP,UR PROTEIN ELECTRO,W/TPROT,S PROTEIN ELECTRO,W/TPROT,S PROTEIN S,ANTIGENIC PROTEIN S,FUNCTIONAL PROTEIN S,FUNCTIONAL	5	Volume	Turn around Time (indicate hours/days)	Price	Performing Lab
PROTEIN ELECTRO,W/TPROT,S PROTEIN ELECTRO,W/TPROT,S PROTEIN S,ANTIGENIC PROTEIN S,FUNCTIONAL PROTEINASE-3 AB	PROF	23			
PROTEIN ELECTRO,W/TPROT,S PROTEIN S,ANTIGENIC PROTEIN S,FUNCTIONAL PROTEINASE-3 AB	PROF	68			
PROTEIN S,ANTIGENIC PROTEIN S,FUNCTIONAL PROTEINASE-3 AB	PROF	80			
PROTEIN S,FUNCTIONAL PROTEINASE-3 AB	85305	37			
PROTEINASE-3 AB	85306	107			
	86021	1			
PROTHROMBIN GENE ANALYSIS	81240	37			
PROTHROMBIN GENE, NY	81240	14			
PROTHROMBIN TIME	85610	1			
PRSS1 GENE, FULL GENE	81404	1			
PSA,FREE	PROFILE	1			
PTH, RELATED PROTEIN	83519	27			
PYRUVATE, BLOOD	84210	2			
QUANTIFERON-TB GOLD		599			
RABBIT EPITHELIA (E82) 1G	86003	-			
RABIES TITER-RESPONSE	86382	2			
RAST	86003	-			
RETICULIN AB (IGA) W/RFX	86255	-			
RHIZOPUS NIGRICANS (M11)	86003	-			
RI AUTOANTIBODY	83520	1			
RIBOSOMAL P PROTEIN AB	83516	5			
RICE (F9) IGE	86003	1			
RICKETTSIAL DISEASE AB	PROFILE	8			
RMSF IGG TITER	86757	2			
RNA POLYMERASE III AB	83520	12			
RNP AB,MULTIPLEX	86235	184			
RPR SCREEN W/TITER RFX	86592	4			
RPR W/TITER & CONF RFX	86592	1			
RUBELLA AB (IGM)	86762	28			
RUBEOLA AB (IGG), EIA	86765	64			
RUBEOLA AB (IGM) TITER,IF	86765	24			
S.PNEUMONIAE IGG AB (23)	86317	2			
SACCHAROMYCES CEREVISIAE	86671	2			
SACCHAROMYCES CEREVISIAE	86671	2			
SALMON (F41) IGE	86003	2			
SARCOPTES SCABIEI DETECTI	87220	2			
SCALLOP (RF338) IgE	86003				
SCL-70 AB,ID	86235	75			
SED RATE, M WESTERGREN, MAN	85651	1			
SELENIUM	84255	5			
HIV 1/2 AG/AB,4TH GEN RFL	87389	93			
HSV 1/2 AB(IGM), W/RFL	PROFILE	99			

RFP 2018 - 009 Attachment 1 - LABORATORY

HIV1/2 AB DI,SUPPLEM HIV-1 INTEGRASE GENOTYPE CT/NG RNA TMA UROGENITAL	CPT	Annual	Turn around Time (indicate hours/days)	Price	Performing Lab
HIV-1 INTEGRASE GENOTYPE	PROFILE	64			
CT/NG RNA TMA UROGENITAL	87906	27			
	PROFILE	80			
HSV 1 IGM TITER 86695	86695	2			
HSV 2 IGM TITER	86696	4			
HERPESVIRUS 6 (IGG,IGM)	86790	2			
SEROTONIN, SERUM	84260	5			
SERTRALINE SERUM/PLASMA	80332	1			
SESAME SEED (F10) IGE	86003	2			
SEX HORMONE BINDING GLOBU	84270	40			
SHOX (GHD) DNA SEQ/DEL.	PROF	9			
SHRIMP (F24) IGE	86003	27			
SIROLIMUS	80195	2			
SIXTEEN MARKERS	PROFILE	1			
SM AB.EIA	86235	184			
SMA CARRIER TEST	81401	-			
SMA DIAGNOSTIC TEST	81401	-			
SMOOTH MUSCLE AB W/RFX	86255	69			
SMOOTH MUSCLE ANTIBODY TI	86256	80			
SOLIDARI F TRANSFERRIN RECE	84238	4			
SOLUBIE LIVER AG ABS	83520	14			
SOMATOSTATIN	84307	-			
SOYBEAN (F14) IGE	86003	7			
SPECIFIC GRAVITY, FLUID	84315	1			
SQUID (F258) IGE	86003	_			
SS-A & SS-B (SJOGREN'S)	86235	208			
STEPWISE INTEG PART 2,NY	PROFILE	340			
STEPWISE PART 1	PROFILE	-			
STEPWISE PART 1, NY	PROFILE	445			
STRAWBERRY (F44) IGE	86003	7			
STREPTOZYME SCR W/RFX TO	86403	2			
STREPTOZYME TITER (RFX)	86406	2			
STRONGYLOIDES AB (IGG)	86317, 86682	2			
SULFHEMOGLOBIN, RBC	83060	1			
SYCAMORE (T11) IGE	86003	1			
SYNTH CANNAB SCR W/CONF,U	80307	0			
T. CRUZI ANTIBODY, IGG	86753	4			
T3 UPTAKE	84479	15			
T3,FREE	84481	10			
T3.REVERSE.LC/MS/MS	84482	45			
T3, TOTAL	84480	1			
T4 FREF DIRECT DIALYSIS	84439	195			

RFP 2018 - 009 Attachment 1 - LABORATORY

Test Name T4,FREE,NON-DIALYSIS TACROLIMUS LC/MS/MS	, i	17-1:			
T4,FREE,NON-DIALYSIS TACROLIMUS LC/MS/MS	7	Noiume	Turn around Time (indicate hours/days)	Price	Performing Lab
TACROLIMUS LC/MS/MS	84439	1			
	80197	46			
TBG	84442	17			
T-CELL CLONALITY PNL, PCR	PROFILE	3			
TESTOSTERONE FREE AND TOT	PROFILE	371			
TESTOSTERONE, TOTAL	84403	34			
TESTOSTERONE;TOTAL	84403	38			
TETANUS ANTITOXOID AB	86774	5			
THALLIUM, BLOOD	83018	93			
THROMBIN TIME	85670	45			
THYROGLOBULIN	PROFILE	178			
THYROGLOBULIN AB	86800	99			
THYROID AB (ATA, TPO)	PROFILE	598			
THYROID PEROXIDASE AB	86376	82			
TICK IDENTIFICATION	87168	1			
TICK IDENTIFICATION		1			
TIMOTHY GRASS (G6) IGE	86003	87			
TISSUE TRANSGLUTAMINASE	83516	2			
TOBRAMYCIN	80200	31			
TOMATO (F25) IGE	86003	10			
TOPIRAMATE	80201	34			
TORCH PROFILE (IGG)	80090	26			
TORCH PROFILE (IGM)	PROFILE	38			
TOXOPLASMA AB	86777	12			
TOXOPLASMA AB (IGG), EIA	86777	80			
TOXOPLASMA AB (IGG,M),EIA	PROFILE	83			
TOXOPLASMA AB (IGM), EIA	86778	6			
TOXOPLASMA GONDII IGG CSF	86777	44			
TPMT ACTIVITY	80375	20			
TRAB (TSH REC BINDING AB)	83519	26			
TRANSFERRIN, SERUM	84466	40			
TRANSGLUTAMINASE AB (IGA)	83516	264			
TRANSPORTATION FEE	99001	107			
TRAZODONE	80338	1			
TREPONEMA PALLIDUM AB, PA	86780	4			
TRIGLYCERIDES PERITONEAL	84478	8			
TRIGLYCERIDES PLEURAL FLU	84478	28			
TRYPTASE	83520	17			
TRYPTOPHAN	82131	1			
TSH	84443	6			
TSH WITH HAMA TREATMENT	84443	4			
TSI	84445	292			

RFP 2018 - 009 Attachment 1 - LABORATORY

		Anticipated Annual			
Test Name	CPT	Nolume	Turn around Time (indicate hours/days)	Price	Performing Lab
TUNA (F40) IGE	86003	1			
TURMERIC IGE	86003	2			
TWENTY FIVE MARKERS	PROFILE	2			
TWENTY FOUR MARKERS	PROFILE	6			
TWENTY THREE MARKERS	PROFILE	14			
TWENTY TWO MARKERS	PROFILE	33			
UREA NITROGEN,24HR URINE	84540	23			
URINALYSIS	81001	1			
URINE CULTURE PRESUMPTIVE	87088	1			
URINE UREA NITROGEN, RAND	84540	4			
UROGRAM	81003	1			
UROGRAM W/MICROSCOPIC RFX	81003	1			
VALPROIC ACID, TOTAL	80164	3			
VARICELLA ZOSTER VIR, PCR	87798	36			
VASOCATIVE INTEST POLYPEP	84586	2			
VDRL,CSF		68			
VDRL,CSF	86592	1			
VENIPUNCTURE PSC		5			
HIV-1 GENOTYPE	PROFILE	4			
HTLV-1/111 AB W/REFL CONF	86790	3			
HTLV1/11,CONFIRM ASSAY	86689	3			
HIV-1 RNA,QL TMA	87535	2			7
HIV-1 RNA, QN, RT-PCR	87536				
HIV-1 DNA,QL,PCR	87535	-			
HERPESVIRUS 7 IGG/IGM,IFA	PROFILE	1			
HIV-1 CORECEP TROPISM, UDS	87902	1			
VIT D 1,25-DIHYDROXY	82652	252			
VITAMIN A	84590	210			
VITAMIN B1 (THIAMINE), B	84425	235			
VITAMIN B1, LC/MS/MS	84425	-			
VITAMIN B2, PLASMA	84252	2			
VITAMIN B6, PLASMA	84207	33			
VITAMIN B7	84591	1			
VITAMIN C,SERUM	82180	189			
VITAMIN D.25-OH, TOTAL, IA	82306	-			
VITAMINE	84446	209			
VITAMIN K	84597	186			
VMA, 24HR URINE W/CREATIN	PROFILE	10			
VMA, RANDOM URINE	PROFILE	3			
VWFAG	85246	16			
VWF AG,MULTIMERIC	85247	10			
VWF, RISTOCETIN CO-FACTOR	85245	20			

RFP 2018 - 009 Attachment 1 - LABORATORY

		Anticipated			
		Annual			
Test Name	CPT	Volume	Turn around Time (indicate hours/days)	Price	Performing Lab
VZV AB (IGG),EIA	86787	132			
VZV AB (IGM), IFA	86787	429			
WALNUT (F256) IGE	86003	2			
WATERMELON IGE	86003	4			
WEST NILE AB IGG,IGM ELIS	PROFILE	51			
WEST NILE AB IGG, IGM ELIS	PROFILE	5			
WHEAT (F4) IGE	86003	23			
WHITE ASH (T15) IGE	86003	7			
WHITE-FACED HORNET (12) I	86003	1			
XSENSE, FRAG X W/RFX	PROFILE	3			
XSENSE, FRAG X W/RFX NY	PROFILE	2			
YEAST ID	87106	22			
YELLOW HORNET (IS) IGE	86003	1			
YELLOW JACKET (13) IGE	86003	1			
ZINC PROTOPORPHYRIN	84202	122			
ZINC TRANSPORTER8(ZNT8)AB	86341	1			
ZINC,PLASMA	84630	222			
ZONISAMIDE	80203	5			

RFP 2018 - 009 Attachment 2 - PATHOLOGY

		j		
TEST NAME	Anticipated Annual Volume	l urn around I ime (indicate hours/days)	Price	Performing Lab
MARIJUANA CONF GCMS, SERU	3			
MARIJUANA, SERUM	3			
PROTEIN ELECTROPHORESIS	21			
DRVVT CONFIRMATION	3			
FISH, HER-2/NEU,PARAF	18			
SEROTONIN RELEASE ASSAY	3			
MICROSATELLITE INSTABILIT	3			
HEPARIN INDUCED PLATELET	18			
IMMUNOFIXATION, URINE	6			
MUM1, IHC W/O INTERP	9			
PROCALCITONIN	09			
EPIDERMAL GROWTH FACTOR	9			
KRAS MUTATION ANALYSIS	9			
EBV, ISH WITH INTERP.	3			
HSV TYPES 1 & 2 W/O INT.	9			
BRAF MUTATION ANALYSIS	15			
NRAS MUTATION ANALYSIS	9			
PDGFRA MUTATION ANALYSIS	3			
LIMITED CONSULTATION	3			
LUPUS ANTICOAG/ANTIPHOS C	3			
IMMUNOHISTOCHEM W/O INTERPRETATION	6			
COLORECTAL CANCER MUT	3			
KI-67, W/O INTERP	102			
BCL-2, IHC W/O INTERP	6			
CD3, IHC W/O INTERP	12			
CD5, IHC W/O INTERP	15			
CD30, IHC W/O INTERP	3			
CD43, IHC W/O INTERP	3			
CD45, IHC W/O INTERP	6			
CD117-CKIT, IHC W/O INTER	6			
CYCLIN D1 IHC W/O INTERP	12			
CYTOKERATIN AE1/AE3 W/O I	42			
E-CADHERIN, IHC W/O INTER	6			

RFP 2018 - 009 Attachment 2 - PATHOLOGY

	Anticipated	Turn around Time		
TEST NAME	Annual Volume	(indicate hours/days)	Price	Performing Lab
ER IHC W/O INTERP	81			
FACTOR 8, IHC W/O INTERP	3			
HER2NEU W/O INTERP	63			
KAPPA IHC W/O INTERP	3			
LAMBDA, IHC W/O INTERP	3			
P53, IHC W/O INTERP	6			
PR, IHC W/O INTERP	93			
BCL-6, IHC W/O INTERP	6			
CALPONIN, IHC W/O INTERP	15			
CALRETININ, IHC W/O INTERP	9			
CD10, IHC W/O INTERP	21			
CD34, IHC W/O INTERP	45			
CD56, IHC W/O INTERP	3			
CD68, IHC W/O INTERP	3			
CD79A, IHC W/O INTERP	3			
CD138, IHC W/O INTERP	9			
CEA, POLYCLONAL W/O INTERP	3			
CYTOKERATIN 5/6 W/O INTERP	42			
CYTOKERATIN 7, IHC W/O INTERP	63			
CYTOKERATIN 19, IHC W/O INTERP	3			
CYTOKERATIN 20, IHC W/O INTERP	21			
EMA, IHC W/O INTERP	9			
FACTOR 13A W/O INTERP	3			
HEPPAR-1 IHC W/O INTERP	9			
MART-1 W/O INTERP	9			
MYOGENIN, IHC W/O INTERP	3			
P63, IHC W/O INTERP	39			
PSA, IHC W/O INTERP	6			
PTH, IHC W/O INTERP	3			
RENAL CELL, IHC W/O INTERP	3			
S100 (POLY), IHC W/O INTERP	30			
S100 (MONO), IHC W/O INTERP	3			
SMOOTH MUSC, IHC W/O INTERP	33			

RFP 2018 - 009 Attachment 2 - PATHOLOGY

Antici  Annual  3  3  1  1  1  1  1  1  1  1  1  1  1	Anticipated Turn around Time Annual Volume (indicate hours/days)  33  21  12  3  9  12  3  9  12  13  15  15  3  3  3  3  3  4  15  3  3  3  3  3  3  3  3  3  3  3  3  3	Price	Performing Lab
AB AB			
11. AB	21 12 3 9 9 12 21 21 3 6 6 6 6 6 15		
11. AB	21 12 3 9 9 12 21 21 3 6 6 6 6 7 15 15 3 3		
L L L L L L L L L L L L L L L L L L L	21 3 9 12 21 21 3 3 6 6 6 6 3 3 3 3 3 3 3 3 3 3 3 3 3		
K (SIS, EVAL	12 9 12 21 3 3 6 6 6 15 3 3		
FYAL  EVAL  O INT  TERP.  TERP  TERP  TERP  TERP  NL, IHC  NL, IHC  NL, IHC  NL, IHC  TERP  TERP	3 21 21 3 3 6 6 6 15 3 3 3		
7 T	9 12 21 3 3 6 6 6 15 3 3 3		
7 T T	12 21 3 6 6 15 15 3 3		
P P P P P P P P P P P P P P P P P P P	21 3 6 6 15 3 3 3		
ERP. ERP. ERP. IFRP. ISH. IN PNL IL, IHC. IL, IHC. FIS. ZUMAB.	3 6 15 3 3 3		
ERP. ERP. ERP. IRP. ISH. IN PNL IL,IHC FIS ZUMAB	3 15 3 3 3 3		
ERP.  ERP.  ERP.  ERP.  IRP.  ICHL  IL, IHC  IL, IHC  FIS  ZUMAB	6 15 3 3 3		
AB AB	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3		
TERP  VITERP  EERP. FISH  ON PNL  NL,IHC  V, FIS  LIZUMAB	8 23 33		
TERP  VITERP  EERP.  TERP.  TIERP.  ON PNL  ON PNL  NL, IHC  V, FIS  LIZUMAB	3 3		
ITERP  NTERP  TERP.  TERP.  FISH  ON PNL  NL,IHC  L, FIS	8		
NL C C C			
INL IC IC AAB	12		
NL IC IC AAB	9		
NL IC IC AAB	15		
	9		
	9		
	3		
	8		
	18		
	9		
	12		
	12		
	18		
CHROMOGRANIN, IHC W/O INTERP 6	9		
DESMIN, IHC W/O INTERP	6		
GFAP, IHC W/O INTERP	6		
HHV-8 IHC W/O INTERP	es.		
HMB45 IHC W/O INTERP	6		
P16. IHC W/O INTERP 54	54		

RFP 2018 - 009 Attachment 2 - PATHOLOGY

	Anticipated	Turn around Time		
TEST NAME	Annual Volume	(indicate hours/days)	Price	Performing Lab
SYNAPTOPHYSIN, IHC W/O IN	24			
WILMS' TUMOR, IHC W/O INT	3			
DRVVT 1:1 MIX	3			

RFP 2018 - 009 Attachment 3 - NIDA

	Anticipated		
	Annual		
TEST NAME	Volume	Turn around Time (indicate hours/days)	Price
DOT DRUG PANEL W/TS	20		
ALCOHOL, ETHYL	8		
SAP 10-50, GC/MS	100		
SAP5-50/2K-3+6A/OX/T	1		
SAP 10-50 W/OPIATES	450		
SAP 6-50, GC/MS	1		
200000000000000000000000000000000000000			

RFP 2018 - 009

Attachment 4 - Stat TAT 2h

	Turn around Time		
	(cannot exceed 2 hours)	Price	Performing Lab
ACETAMINOPHEN			
AFB SMEAR			
AMIKACIN			
AMMONIA			
AMYLASE			
BASIC METABOLIC PANEL			
BASIC METABOLIC PANEL			
BETA HCG			
BLOOD GAS (ARTERIAL)			
BLOOD GAS & CORBOXYHEM			
BLOOD GAS & ELECTROLYTES			
BLOOD GAS, ELECTROLYTES, GLUCOSE & LACTICE ACID			
BLOOD GAS & 02 SATURATION			
BLOOD GAS & OXIMETRY			
BLOOD GAS AND ELECTROLYTES			
BLOOD GAS AND 02 SATURATION			
BLOOD GAS ELECTROLYTES & METABOLYTES			
CALCIUM			
CARBAMAZEPINE			
CARBON MONOXIDE			
CARBOXYHEMOGLOBIN			
CARDIAC MARKERS			
CBC			
CBC DIFF			
CHLORIDE			
COMPREHENSIVE METABOLIC PANEL			
005			
CPK			
CPKMB			
CREATININE			
CRYPTOCOCCAL AG CSF			
CSF CELL COUNT			

RFP 2018 - 009 Attachment 4 - Stat TAT 2h

	Turn around Time		
	(cannot exceed 2 hours)	Price	Performing Lab
CSF GLUCOSE			
CSF LACTATE			
CSF LDH			
CSF POTASSIUM			
CSF PROTEIN			
CSF SODIUM			
CSF VDRL			
D-DIMER			
DETOX PANEL			
DIGOXIN			
DIRECT BILIRUBIN			
ESR			
ETHANOL			
FETAL FIBRONECTIN			
FIBRINOGEN LEVEL			
FROZEN SECTION			
GENTAMICIN			
GLUCOSE			
GLUCOSE 50g CHALLENGE			
2Hr. POST GLUCOSE CHALLENGE			
GLUCOSE TOLERANCE			
GRAM STAIN (ALL BODY FLUIDS)			
HEPATITIS B SURFACE ANTIGEN			
INDIA INK (CSF AND PLEURAL)			
IONIZED CALCIUM			
LACTATE			
LIPASE			
LITHIUM			
MAGNESIUM			
MALARIA SCREEN			
MATERNAL, NEWBORN & OCCUPATIONAL HIV 1 AG/AB			
SCREENS			

RFP 2018 - 009 Attachment 4 - Stat TAT 2h

	Turn around Time	()	
	(cannot exceed z nours)	Price	Periorming Lab
PHENOBARBITAL			
PHENYTOIN	W		
PLATELET COUNT			
POTASSIUM			
РТ			
РТТ			
RAPID MOLECULAR INFLUENZA			
RETICULOCYTE COUNT			
RUPTURE OF MEMBRANE			
SALICYLATE LEVEL			
SERUM/PLASMA KETONES			
SODIUM			
SPINAL FLUID CELL COUNT			
STOOL for OCCULT BLOOD			
THEOPHYLLINE			
TOTAL BILIRUBIN			
TROPONIN I			
TSH			
TYPE & SCREEN			
nce			
UREA NITROGEN			
URIC ACID			
URINALYSIS			
URINE DRUG SCREEN			
VALPROIC ACID			

RFP 2018 - 009 Attachment 5 -Other Tests (as needed)

	į		
TEST NAME	Turn around Time (indicate hours/days)	Price	Performing Lab
24HR U OSMOLALITY			
24HR UCA PANEL			
24HR UCL PANEL			
24HR UCR PANEL			
24HR UGLU PANEL			
24HR UK PANEL			
24HR UNA PANEL			
24HR UPROT PANEL			
24HR UURC PANEL			
2HR PP GLUCOSE TOL.			
50g GLU CHALLENGE			
ABG & OXIMETRY			
ABG AND ELECTROLYTES			
ABG LYTES & METABOLYTES			
ABG W/ O2 SATURATION			
ALK PHOS			
ALT			
AMIKACIN LEVEL			
AMIKACIN PEAK LEVEL			
AMIKACIN TROUGH LEVEL			
ANTI-NUCLEAR AB			
ANTIMONY, URINE			
ARTERIAL BLOOD GAS			
AST			
BETA STREP SCREEN			
BICARBONATE			
BLD ISOLATOR/FUNGAL			
BLOOD CULTURE/FUNGUS			
BLOOD CULTURE			
BLOOD ISOLATOR-BACTI			
BLOOD OXIMETRY			
BODY FLUID AMYLASE			

RFP 2018 - 009 Attachment 5 -Other Tests (as needed)

	1000		
TEST NAME	l urn around Time (indicate hours/days)	Price	Performing Lab
BODY FLUID CELL COUNT			
BODY FLUID CHLORIDE			
BODY FLUID DIFFERENTIAL			
BODY FLUID GLUCOSE			
BODY FLUID LDH			
BODY FLUID LYTES			
BODY FLUID PH			
BODY FLUID POTASSIUM			
BODY FLUID PROTEIN			
BODY FLUID SODIUM			
BONE CULTURE			
BRONCHIAL LAVAGE COUNT			
C-REACTIVE PROTEIN			
C.DIFFICILE TOXIN A/B AND ANTIGEN			
CARBAMAZEPINE LEVEL			
CATHETER TIP CULTURE			
CEA			
CHLAMYDIA PNEUMONIA			
CHLAMYDIA TRACH.			
CHLAMYDIA TRACHOMATIS			
CHOLESTEROL			
CKMB (MASS)			
COMPLEMENT C3 FRACT			
COMPLEMENT C4 FRACT			
COMPREHENSIVE METAB.			
CORTISOL			
CREATINE KINASE			
CRYPTOCOCCAL AG-BLD			
CRYPTOSPORIDIUM			
CT/GC NAT COMBO			
CULTURE AFB			
CULTURE BODY FLUIDS			

RFP 2018 - 009 Attachment 5 -Other Tests (as needed)

TEST NAME	(indicate hours/days)	Price	Performing Lab
CULTURE FUNGAL			
CYTOLOGY, GYN AND NON-GYN			
CYTOMEGALOVIRUS CUL			
DIALYSIS PROFILE			
DIRECT BILIRUBIN			
EAR CULTURE			
ELECTROLYTES			
ENA SMITH & RNP			
ENA SS-A & SS-B			
ESR			
ESTRADIOL			
EYE CULTURE			
FACTOR XII			
FACTOR XI			
FACTOR X			
FAT C. TRACHOMATIS			
FAT FOR HSV			
FAT FOR RSV			
FAT FOR VZV			
FAT PARAFLU			
FERRITIN			
FLUID CULTURE			
FOLATE			
FREE T4 INDEX & T3			
FREE T4 INDEX PANEL			
FREE T4			
FSH			
FUNGAL CULTURE ROUTINE			
G-6-PD			
GC CULTURE			
GENITAL CULTURE			
GENTAMICIN LEVEL			

RFP 2018 - 009 Attachment 5 -Other Tests (as needed)

	1000		
TEST NAME	l urn around I Ime (indicate hours/days)	Price	Performing Lab
GENTAMICIN PEAK LEVEL			
GENTAMICIN TROUGH LEVEL			
GESTATIONAL GLU TOL			
GGT			
GLUCOSE,RANDOM			
GRAM STAIN ONLY			
HAPTOGLOBIN			
HEPATITS A VIRUS AB (IGM)			
HEPATITIS A VIRUS AB, TOTAL			
HB CORE AB, TOTAL			
HGB F			
HEPATITIS B SURFACE AB			
HC VIRAL AB SCREEN			
НСТ			
HEPATITIS C VIRUS AB SCREENING			
HEMOGLOBIN A1C			
HEP B IgM CORE Ab			
HEP B CORE AB TOTAL	0		
HEP B SURFACE Ag			
HGB ELECTROPHORESIS			
HGB			
IMMUNOGLOBULIN A			
IMMUNOGLOBULIN D			
IMMUNOGLOBULIN G/A/M			
IMMUNOGLOBULIN G			
IMMUNOGLOBULIN M			
INHIBITOR SCREEN			
IRON PANEL			
IRON			
JOINT FLUID CRYSTAL ID			
LACTATE, WHOLE BLOOD			
ГДН			

RFP 2018 - 009 Attachment 5 -Other Tests (as needed)

i i	Turn around Time	Č	
IESI NAME	(indicate nours/days)	Price	Penorming Lab
LIPID PANEL			
LITHIUM LEVEL, SERUM			
LUTEINIZING HORMONE			
MD SMEAR			
MISCELLANEOUS C/S			
MONO TEST			
MRSA SCREEN			
NASOPHARYNGEAL CULTURE			
NEISSERIA GONORRHOEAE			
NEONATAL CREATININE			
NON-GEST GLUCOSE TOL			
NUTRITION ASSESSMENT			
OVA AND PARASITES			
PARASITOLOGY EXAM			
PERIOD AND VOLUME			
PERITONEAL EQUILIB.1			
PERITONEAL EQUILIB.2			
PERITONEAL EQUILIB.3			
PERITONEAL EQUILIB.4			
PERITONEAL EQUILIB.5			
PERITONEAL LAVAGE			
PET CREATININE			
PET GLUCOSE			
PET UREA N.			
PHOSPHOROUS			
PINWORM PREPARATION			
PREALBUMIN			
PROGESTERONE			
PROLACTIN			
PSA-DIAGNOSTIC			
PSA-SCREENING			
PTT			

RFP 2018 - 009 Attachment 5 -Other Tests (as needed)

TEST NAME	Turn around Time	D	Derforming Lab
TO	(-6		D
RANDOM URINE PROTEIN			
RAPID FLU A TEST			
RAPID INFLUENZA B			
RAPID HIV 1 AG/AB SCREEN			
RBC			
RESP DEPT ABG & sO2			
RESPIRATORY CULTURE			
RESPIRATORY V C			
RETICULOCYTE			
RHEUMATOID FACTOR			
ROTAVIRUS			
RPR			
RUBELLA AB (IGG)			
SALINE SUSPENSION			
SERUM OSMOLALITY			
SICKLE CELL SCREEN			
SPINAL FLUID VDRL			
STOOL CULTURE			
STOOL REDUCING SUBSTANCE			
SURGICAL PATHOLOGY			
T-UPTAKE			
THEOPHYLLINE LEVEL			
THROAT CULTURE			
THYROID PANEL			
THYROXINE			
TISSUE CULTURE			
TOTAL BETA HCG			
TOTAL BILIRUBIN			
TOTAL EOSINOPHIL COUNT			
TOTAL PROTEIN			
TRIGLYCERIDES			

RFP 2018 - 009 Attachment 5 -Other Tests (as needed)

	H		
TEST NAME	(indicate hours/days)	Price	Performing Lab
TRIIODOTHYRONINE			
TROPONIN T			
TSH-3RD GEN			
U MICROALBUMIN PANEL			
U SODIUM/POTASSIUM			
URINE CALCIUM			
URINE CHLORIDE			
URINE CREATININE			
URINE CULTURE			
URINE DRUG SCREEN			
URINE EOSINOPHILS			
URINE GLUCOSE			
URINE KETONE			
URINE MICROALBUMIN			
URINE OSMOLALITY			
URINE POTASSIUM			
URINE PREGNANCY			
URINE REDUCING SUBSTANCE			
URINE SODIUM			
URINE SPEC GRAVITY			
URINE URIC ACID			
VALPROIC ACID LEVEL			
VANCOMYCIN LEVEL, PEAK			
VANCOMYCIN LEVEL, TROUGH			
VANCOMYCIN LEVEL			
VENOUS BLOOD GAS			
VIRAL CULTURE			
VIRAL QUANTITATION			
VITAMIN B12			
VITAMIN D			
VRE SCREEN			
WHOLE BLOOD CHLORIDE			

RFP 2018 - 009

Attachment 5 -Other Tests (as needed)

	Turn around Time		
TEST NAME	(indicate hours/days)	Price	Performing Lab
WHOLE BLOOD CREATININE			
WHOLE BLOOD GLUCOSE			
WHOLE BLOOD LYTES			
WHOLE BLOOD POTASS.			
WHOLE BLOOD SODIUM			
WOUND CULTURE			